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ABSTRACT 
CXCR4 is a chemokine receptor that is overexpressed in multiple disease states, 
including cancer. Understanding the mechanisms by which cells regulate CXCR4 
expression is of high importance, as they can reveal downstream effectors that can 
potentially be targeted pharmacologically to more effectively treat diseases with fewer 
side effects. 
CXCR4 is internalized in response to stimulation by its ligand CXCL12, and 
localizes to early endosomes as part of a homologous desensitization mechanism. From 
the endosome, CXCR4 can enter one of two pathways whereby it is either recycled back 
to the plasma membrane, where it can undergo another signaling event, or it is targeted 
for lysosomal degradation via the ESCRT pathway in a ubiquitin-dependent fashion. It is 
known that an interaction between the proteins β-arrestin-1 and STAM-1 (a subunit of 
ESCRT-0) on endosomal membranes plays a key role in sorting CXCR4 to the 
degradative pathway, and that disrupting this interaction can accelerate CXCR4 
degradation. Therefore, the β-arrestin-1/STAM-1 complex represents a potential target by 
which to modulate cellular CXCR4 levels. 
The goal of this project was to develop an assay that can monitor the interaction 
between β-arrestin-1 and STAM-1 in live cells, which can be used to study their binding 
under various conditions. An important use of the assay could be to assess the ability of 
various small molecules to interrupt this interaction, which could potentially be
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developed as novel therapeutics for the treatment of diseases that overexpress CXCR4. In 
addition, the assay could be applied to a variety of experiments in order to further 
elucidate the mechanisms by which the β-arrestin-1/STAM-1 complex interacts with of 
other proteins to modulate the sorting of CXCR4 on endosomes. 
The assay designed in this project utilizes bioluminescence resonance energy 
transfer (BRET) as a measurement of the interaction status by the co-expression of 
STAM1-Rluc (Renilla luciferase) with β-arrestin1-YFP. The addition of a 
coelenterazine(h) substrate induces the emission of light from Rluc, which is absorbed by 
the yellow fluorescent protein (YFP) and emitted at a different wavelength, if the proteins 
are interacting. It was expected that expression of the two fusion proteins would yield a 
relatively low BRET signal in cells that had not been stimulated with CXCL12. However, 
following CXCL12 stimulation, a significantly higher BRET signal was expected, since 
CXCR4 is rapidly internalized to endosomes upon ligand binding. 
After attempting to use BRET to detect an interaction between two proteins 
whose interaction has already been shown by BRET, and using BRET to examine the 
interaction between two proteins that are not expected to interact, it was determined that 
BRET measurements between STAM1-Rluc and β-arrestin1-YFP were likely showing a 
slight interaction between the two proteins. No differences were seen in BRET between 
cells stimulated with CXCL12 or vehicle. It is concluded from the obtained results that 
further optimization steps are required for the assay described here to be amenable to any 
future studies of the interaction between STAM-1 and β-arrestin-1.
 1 
CHAPTER 1 
INTRODUCTION 
Overview of G Protein-Coupled Receptors 
 G protein-coupled receptors (GPCRs) are a superfamily of proteins that are 
mainly characterized by the possession of seven membrane-spanning domains, 
functioning as cellular surface receptors that propagate signals from the outside to the 
inside of the cell. 1  GPCR signaling is highly conserved across many different organisms, 
and plays a role in a multitude of signaling pathways in humans. 1  As such, the 
dysfunctioning of GPCRs is associated with a large number of human diseases, with 
almost half of currently available drugs targeting GPCRs. 2   
GPCR signaling occurs via the binding of an extracellular ligand to the receptor’s 
N-terminus, causing a conformational change, which, in turn, allows the intracellular C-
terminal domain to interact with proteins in the cytosol. 1  In classical GPCR signaling, 
the intracellular domain of the receptor couples to a membrane-bound heterotrimeric G 
protein. 3  G proteins are guanine nucleotide-binding proteins that bind GDP in their 
inactive form and release GDP upon coupling to GPCRs, which causes binding of GTP in 
its place. 4  The binding of GTP initiates propagation of signaling through G protein 
activation of effector proteins. G proteins contain α, β, and γ subunits, and their multiple 
subfamilies are typically defined by the isoform combination of the α and βγ dimer  
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subunits, with each combination interacting with different effector proteins to initiate 
different cellular signaling pathways. 5  
 
 
Figure 1. Classical “G Protein-Dependent” GPCR Signaling. Coupling of the ligand-
bound receptor to an inactive G protein causes a conformational change in the α subunit, 
resulting in the release of GDP. Binding of GTP to the α subunit causes dissociation of 
the α subunit from the GPCR and from the βγ dimer. Each component is now activated 
and capable of activating effector proteins. 
 
CXCR4 
 CXCR4 is a GPCR that functions as a chemokine receptor. Chemokines are 
signaling peptides secreted by cells, which act as local mediators of cell-cell 
communication, with their most classic function being to chemically attract cells to 
migrate in certain directions (known as chemotaxis). 6  CXCR4 is important in various 
cellular signaling pathways involved in embryogenesis, in the development of the heart, 
brain, and vasculature. 7, 8  It is important, non-embryonically, in stem cell homing to the 
bone marrow during hematopoiesis and mediation of immune cell trafficking in 
inflammation. 9, 10  CXCR4 is also involved in immune cell invasion, cell adhesion, cell 
survival, angiogenesis, and tissue repair mechanisms. 11  
CXCR4 Signaling 
CXCR4 binds almost exclusively to the C-X-C Ligand 12 (CXCL12, which is 
sometimes referred to as SDF-1). Binding of CXCL12 to CXCR4 initiates signaling 
  
3 
pathways in the cell that mediate cell migration, adhesion, survival, and proliferation 
processes. 12   
CXCR4 most often couples with Gi proteins. 13  Activation of the Gαi subunit 
inhibits adenylyl cyclase, resulting in a decrease in the intracellular level of the second 
messenger cyclic adenosine monophosphate (cAMP). Activated Gαi subunits can also 
activate Src proteins. In addition, the activated βγ dimer in the CXCR4 G protein-
dependent pathway can contribute to activation of AKT signaling by activating PI3K 
(Phosphoinositide 3-Kinase). 13  
Another example of CXCR4 signaling occurs through the binding of β-arrestin 
proteins to activated CXCR4, which act as signaling scaffolds that interact with 
downstream effector proteins of various signaling pathways. 14  In particular, a complex 
formed between β-arrestin-1 and STAM-1 proteins with CXCR4 on endosomal 
membranes has been shown to be involved in promoting autophosphorylation of FAK 
(focal adhesion kinase) proteins in response to CXCR4 activation, leading to cell 
migration. 15 In addition, disrupting this interaction was shown not to disrupt activation of 
ERK1/2 or AKT signaling through G protein coupling. 
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Figure 2. CXCR4 G Protein-Dependent Signaling Cascade. 16  Some of the known 
signaling pathways that are mediated by the actions of CXCR4 include such functional 
cellular outcomes as proliferation, migration, and survival. 
 
CXCR4-Related Disease States 
 It was first realized that CXCR4 was pathologically involved in disease when it 
was discovered that HIV utilized CXCR4 as a co-receptor to invade helper T-cells. 17  
CXCR4 has since been found to be involved in a number of other diseases including 
cardiovascular disease, WHIM (Warts, Hypogammaglobulinemia, Immunodeficiency, 
and Myelokathexis) syndrome, and cancer. A major component of the pathology of 
disease states involving CXCR4 is a dysregulation of CXCR4 expression.  
In particular, CXCR4 overexpression is seen in at least 23 different types of 
cancer. This is not entirely surprising considering the developmental, homeostatic, and 
migratory roles that CXCR4 signaling can play in certain healthy tissues, an over 
activation of which would be, assumingly, beneficial to tumor growth and malignancy. 18  
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Evidence of this exists in that CXCR4 has been shown to mediate adhesion of cancer 
cells to stromal cells stimulating tumor cell proliferation, migration, invasion, survival, 
and neoangiogenesis. 19-24   
Interestingly, CXCR4 overexpression has also been shown to play an important 
role in the metastasis of cancer, in that certain tissues constitutively expressing CXCL12, 
such as the bone marrow, lung, liver, and brain, can cause cancer cells overexpressing 
CXCR4 to home to and invade these tissues as a result of CXCL12 signaling. 25 A 
specific example of CXCR4 overexpression playing a role in metastasis can be seen in 
breast cancer cells, where the CXCR4/CXCL12 signaling axis can mediate actin 
polymerization, resulting in the formation of pseudopodia and increased potential for 
chemotaxis and metastasis of breast cancer cells. 26   
CXCR4 Antagonists as Therapeutics 
There has been an effort to utilize CXCR4 antagonists in the treatment of certain 
cancers, however the only drug that is currently approved by the FDA is Plerixafor (Also 
known as Mozobil and AMD-3100). Plerixafor was first developed for treatment of HIV, 
but this was abandoned because it was not effective against M-tropic CCR5 HIV strains, 
and because of its poor oral bioavailability. 27  However, Plerixafor eventually received 
approval by the FDA for use in combination with granulocyte colony-stimulating factor 
(GCSF) to mobilize hematopoietic stem cells to the bloodstream in order to be collected 
and transplanted autologously into patients with Non-Hodgkin’s Lymphoma and Multiple 
Myeloma. 28   
Some of the side-effects from Phase I/II trials that Plerixafor underwent for anti-
HIV uses included increase in white blood cells, and cardiac arrhythmia. 29  
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Overproduction of white blood cells, or hyperleukocytosis, is dangerous because it 
results in increased blood viscosity and hematological stasis, and can predispose patients 
to neurological and gastrointestinal complications. However, use of Plerixafor combined 
with GCSF in Phase I-III clinical trials demonstrated that it had minimal side-effects, in 
part because of its relatively short time-frame of administration needed to mobilize stem 
cells when compared to the time-frame of administration needed in treatment of HIV. 30  
It has also been attempted to use CXCR4 antagonists against multiple types of cancers, 
however none, as yet, have achieved FDA approval for such use.  
The use of CXCR4 antagonists in the prevention of cancer metastasis is of great 
interest due to the known role of the CXCR4/CXCL12 signaling axis in homing of 
malignant cells to secondary tissues. T140 analogs are short peptide CXCR4 antagonists 
that have been shown to effectively reduce metastasis in addition to primary growth of 
breast cancer in mouse models. 31 However, to date, neither T140 analogs, nor any other 
class of CXCR4 antagonists, have been approved by the FDA for such use, which is not 
wholly surprising considering the known side-effects that can occur when administering 
CXCR4 antagonists in humans. Thus, there is a clear need for novel therapeutic agents 
that target downstream effectors involved in the mediation of CXCR4 expression and/or 
migration-related signaling (FAK), which can potentially disrupt the ability of malignant 
cells to migrate without disrupting the other signaling pathways that are necessary for 
homeostatic functions in healthy cells. 
CXCR4 Regulation 
 The clinical relevance of CXCR4 overexpression in disease states makes the 
understanding of the manner in which CXCR4 levels are regulated in healthy cells of 
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great importance, as it can give insight into which mechanisms within the pathway can 
potentially be targeted pharmacologically to decrease CXCR4 signaling more effectively 
and with fewer side effects.  
The natural mechanism for lowering CXCR4 signaling in cells classically occurs 
through homologous desensitization of the receptor, which is a rapid, but transient, 
inactivation of signaling through the activated receptor. This occurs through a 
desensitization process that is typical to GPCRs, where binding of the ligand induces 
phosphorylation of the intracellular domain of the receptor by a G Protein Receptor 
Kinase (GRK) enzyme. 32  The phosphorylation of the receptor recruits β-arrestin proteins 
to bind CXCR4 at the phosphorylated sites, which serves to sterically hinder the 
activation of additional G proteins, as well as to recruit proteins that promote 
internalization of the receptor onto early endosomes. 32, 33  Removal of CXCR4 from the 
cell surface prevents further ligand-mediated activation of signaling through the receptor.  
Once internalized, CXCR4 is sorted to one of two pathways. One is a recycling 
pathway, through which CXCR4 is trafficked back to the plasma membrane, where it can 
undergo another ligand-mediated signaling event in a process called “re-sensitization.” 34, 
35  The other pathway that CXCR4 can enter is a degradative pathway, where it is 
trafficked to lysosomes via multi vesicular bodies (MVBs) where the receptor is 
subsequently degraded. 36  The degradation of CXCR4 causes its signal to be attenuated 
and prevents the receptor from undergoing additional ligand-mediated signaling events, 
causing longer-term “downregulation” of CXCR4 signaling.  
Knowing this mechanism of regulation provides a potential target for adjusting 
the balance between the recycling and degradation pathways in order to modulate the 
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magnitude of receptor expression. For instance, it has been shown that interrupting the 
interactions between β-arrestin-1 and STAM-1 proteins in HeLa cells accelerates 
degradation of CXCR4, which could be utilized to influence downregulation of CXCR4 
in diseased cells. 37  
 Endocytosis. CXCR4 can be internalized into cells through a mechanism of 
classical, dynamin-dependent endocytosis mediated by β-arrestin. 33  The binding of β-
arrestin to phosphorylated sites on the intracellular domain of the receptor causes a 
conformational change in β-arrestin, allowing it to bind clathrin and AP2 proteins that 
cause endocytosis of the receptor via clathrin-coated pits. 38  There is evidence, however, 
that CXCR4 is also capable of undergoing endocytosis in a β-arrestin-independent 
mechanism. 39  
 Endosomal Sorting. Once endocytosed, CXCR4 receptors localize onto early 
endosomes. The early endosome is a sorting station within the cell where different post-
translational modifications and protein interactions determine whether CXCR4 will be 
shuttled into the degradative pathway or be recycled back to the plasma membrane for 
further signaling.  
The majority of CXCR4 is shuttled into the degradative pathway in response to 
CXCL12 stimulation. 13 However, a small amount of receptors are recycled back to the 
membrane via Rab-11-positive recycling endosomes. 40   
Ubiquitination of CXCR4 by the Atropin-1-Interacting Protein 4 (AIP4) shortly 
after binding CXCL12 is a post-translational modification that helps direct CXCR4 into 
the degradative pathway. 36, 41  This occurs through interactions with the Endosomal 
Sorting Complexes Required for Transport (ESCRT) machinery, which functions to 
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concentrate the ubiquitinated receptor into clathrin-coated pits within the endosomal 
membrane that pinch off to form intraluminal vesicles (ILVs) within multi vesicular 
bodies (MVBs) (Figure 3). 42  The MVBs subsequently fuse with lysosomes, leading to 
the degradation of the receptor.  
Interaction of β-arrestin-1 with CXCR4 on the endosomal membrane also plays 
an important role in the mediation of CXCR4 trafficking to the lysosome. It has been 
shown that β-arrestin-1 can act as a positive regulator of CXCR4 degradation, since 
siRNA knockdown of β-arrestin-1 causes a decrease in the degradation of CXCR4. 43  
However, it has also been shown that interaction between β-arrestin-1 and a subunit of 
the ESCRT-0 protein serves to negatively regulate the rate at which CXCR4 is shuttled 
into the degradative pathway. ESCRT-0 is a protein complex consisting of two subunits 
known as HRS and STAM-1. It has been shown that a ubiquitin-interacting motif (UIM) 
on HRS binds the ubiquitin moiety on CXCR4, and that a direct interaction between β-
arrestin-1 and the STAM-1 subunit on ESCRT-0 occurs when β-arrestin-1 is recruited to 
the receptor on the endosomal membrane. 37, 41  Moreover, it has been shown that this 
interaction is responsible for a negative regulatory role of CXCR4 degradation, as 
STAM-1 siRNA-mediated disruption of the interaction between these two proteins causes 
an attenuation of CXCR4-mediated HRS ubiquitination, and thus enhanced CXCR4 
degradation. 37  It is possible that β-arrestin-1 initially directs CXCR4 to ESCRT-0, and 
that this is followed by an interaction with STAM-1 that attenuates CXCR4 degradation. 
It is thought that the interaction between β-arrestin-1 and STAM-1 serves to modulate the 
ubiquitination status of HRS by acting as an adaptor protein for AIP4 to ubiquitinate 
HRS, and that a poly-ubiquitination of HRS attenuates the sorting of CXCR4 into the 
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degradative pathway. This is thought to occur through an autoinhibitory interaction 
between the ubiquitin moiety added to HRS and its own internal UIM. This causes HRS 
to dissociate from the receptor and prevents recruitment of the remaining ESCRT 
machinery, thus preventing budding of the receptor from the endosomal membrane into 
ILVs. Occasionally, the interaction between ESCRT-0 and CXCR4 is able to remain 
stable for long enough to allow the remaining components of the ESCRT machinery 
(ESCRTI-III) to be recruited to the receptor on the endosomal membrane, initiating 
budding of the receptor into ILVs. Thus, the interaction between β-arrestin-1 and STAM-
1 serves to slow the process of lysosomal degradation of CXCR4 that normally occurs 
very easily, and it is conceivable that interrupting these interactions would accelerate the 
lysosomal degradation of CXCR4. 
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Figure 3. CXCR4 Homologous Desensitization Pathway. CXCR4 enters either a 
recycling or a degradative pathway. The interaction between STAM-1 and β-Arrestin-1 
facilitates a negative regulatory mechanism causing ESCRT-0 to dissociate from the 
receptor and preventing the recruitment of further ESCRT machinery. 
 
To date, the interaction between β-arrestin-1 and STAM-1 has not been shown to 
take part in the trafficking of any other receptors besides the endosomal sorting of 
CXCR4. It has been shown that the interaction is not involved in EGFR degradation (an 
RTK known to interact with ESCRT-0 as part of its endosomal sorting process), as its 
degradation was unaffected by the expression product of a minigene (β-arrestin-1 “25-
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161”) that acts as a competitive inhibitor of STAM-1/β-arrestin-1 binding. 37  Further, 
it has been shown that STAM-2 is not involved in the endosomal sorting of CXCR4. 37   
Bioluminescence Resonance Energy Transfer (BRET) 
Because it has been shown that the disruption of the interaction between β-
arrestin-1 and STAM-1 can cause accelerated degradation of CXCR4, and because this 
would be desirable in diseased cells that have an overexpression of CXCR4, there is 
motive to design an assay with which the status of the interaction between these two 
proteins is indicated. This assay could then be used to search for small molecules that 
have the ability to disrupt this interaction. 
Certain proteins possess the ability to absorb light energy at certain wavelengths, 
causing their electrons to become excited in such a way that when the electrons 
eventually relax to their ground state, light energy is released at a wavelength within the 
visible spectrum. 44  This phenomenon is known as fluorescence. Some fluorescent 
proteins emit fluorescence energy at a wavelength that is capable of causing excitation of 
other fluorescent proteins, after which they emit their own wavelength of fluorescence. 
This phenomenon is known as resonance energy transfer (RET) and can occur in cells 
when the two expressed fluorescent proteins are within 10-100Å of one another. 45  
This phenomenon can be utilized to study protein-protein interactions in live cells 
by genetically fusing the two fluorescent proteins separately to two different proteins of 
interest that are thought to interact in the cell. Typical interactions between proteins are 
sufficient to bring the fluorescent proteins in close enough proximity for RET to occur. 
Therefore, light of a specific wavelength can be shone onto cells expressing the two 
fusion proteins to cause the “donor” moiety to become excited and, if the two proteins are 
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interacting, RET will occur and a fluorescence will be observed at the wavelength 
characteristic to the “acceptor” moiety. This technique is known as Fluorescence 
Resonance Energy Transfer (FRET). 46  
A major disadvantage of FRET is that shining light onto the cells to cause 
excitation of the donor moiety can cause photobleaching, decreasing the signal:noise ratio 
and making the assay less sensitive to the level at which the proteins are interacting with 
one another. 47  Another disadvantage to FRET is that the wavelength at which the two 
fluorescent moieties become excited is a range rather than one wavelength, and shining 
light on the cells can cause transient excitation of the acceptor moiety, leading to false 
positive readings if the excitation spectrum of the acceptor moiety is close to that of the 
donor moiety.  
 Certain proteins, however, are capable of undergoing reactions with certain 
chemical substrates that cause the same type of electron excitation and light energy 
emission that is seen in fluorescence. Light energy that is released as a result of this type 
of chemical excitation is called bioluminescence, and can be utilized in the same way to 
study protein-protein interactions. This can be carried out by replacing the donor moiety 
from FRET with a bioluminescent moiety, and adding the substrate that causes excitation 
of the bioluminescent moiety to the cells in order to initiate RET. 48  This technique is 
referred to as Bioluminescence Resonance Energy Transfer (BRET). One of the main 
advantages of this technique is that the chemical reaction eliminates the need for light 
excitation and thus, eliminates the possibility of photobleaching, making the assay much 
more sensitive to small amounts of light emission. 
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 The majority of BRET experiments utilize a bioluminescent protein (Rluc) 
found in the Renilla Reniformis sea pansy that endogenously reacts with a protein called 
coelenterazine to emit bioluminescence. 49  The first form of experimental BRET 
developed, referred to as BRET1, utilizes a humanized derivative of coelenterazine to 
react with Rluc causing bioluminescent emission at a wavelength of ~470 nm. In BRET1 
Rluc is paired with a yellow fluorescent protein (YFP) acceptor that absorbs the light 
emitted at ~470nm and emits yellow fluorescent light at ~530nm. 48  A further optimized 
form of BRET (BRET2) utilizes another modified derivative of coelenterazine, known as 
DeepBlueC©, which causes Rluc to emit light at 400 nm. 50  In BRET2 Rluc is paired 
with a green fluorescent protein (GFP) acceptor, which absorbs the light emitted by Rluc 
at 400nm and emits green fluorescent light at 510nm. The advantage of BRET2, when 
compared to BRET1, is that it yields a better spectral emission (the difference between 
donor and acceptor emissions) and increases the signal:noise ratio of measurements 
taken. BRET1, however, has the advantage that a longer reaction duration occurs between 
Rluc and coelenterazine(h) (~1 hour) when compared to a reaction duration of only few 
minutes for DeepBlueC©. Evidence of these fluorophores successfully yielding a quality 
BRET signal when fused to two proteins that are related to this project can be seen in a 
recent study that utilized CXCR4-Rluc and β-arrestin2-GFP fusion proteins. 51  
 BRET experiments typically use a plate reader to measure both the 
bioluminescence emission level of Rluc as well as the fluorescence emission level of the 
fluorescent acceptor. This is due to the fact that any bioluminescence emission is a result 
of Rluc not being in close enough proximity to the fluorescent moiety for it to absorb the 
energy, and therefore the level of bioluminescence emission measured is indicative of the 
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level at which the two proteins of interest are not interacting. This measurement can be 
used in conjugation with the amount of fluorescence measured in order to quantitatively 
calculate the level at which the proteins are interacting in the cell by calculating a “BRET 
Ratio.” A BRET ratio is simply the measured level of fluorescence divided by the level of 
measured bioluminescence. 47  
 
 
Figure 4. Bioluminescence Resonance Energy Transfer (BRET). (a) Graphical 
representation of the phenomenon of bioluminescence. (b) A graphical representation of 
interactions that allow BRET2 measurements to be made. A similar interaction occurs in 
BRET1, however DeepBlueC is replaced by coelenterazine(h), GFP is replaced with YFP, 
and different emission wavelengths occur. 
 
The BRET technique as described above is an attractive assay with which to 
monitor the interaction between β-arrestin-1 and STAM-1 because it allows monitoring 
of these interactions in live cells and it provides a high signal to noise ratio, when 
compared with other assays. To develop this assay, Rluc and either YFP or GFP moieties 
need to be fused to either protein in an appropriate location so as not to disrupt the 
normal ability of these proteins to interact with one another. 
β-Arrestin-1 
 There exist two isoforms of β-arrestin, β-arrestin-1 and β-arrestin-2. They are 
known as the “non-visual” arrestins, because both are found ubiquitously throughout all 
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human cell types, unlike the rhodopsin-like isoforms found in rod and cone cells 
(known simply as arrestins). In general, β-arrestin-1 and β-arrestin-2 differ with respect 
to CXCR4 signaling, however, in that β-arrestin-2 is involved in the internalization of the 
receptor, whereas β-arrestin-1 is more involved in endosomal trafficking. 33, 43  It has been 
established that both isoforms interact with phosphorylated residues on receptors via 
positively charged amino acids near their N-terminus. 52  Therefore, it is logical that any 
fusion protein made of β-arrestin should contain the attached moiety within either the C-
terminus or somewhere in the middle of β-arrestin’s amino acid sequence. 
STAM-1  
As stated previously, STAM-1 is the protein within the ESCRT-0 protein complex 
that binds β-arrestin-1 in the endocytic trafficking of CXCR4. STAM-1 can also exert 
signaling functions, nevertheless, this project will focus on its role as a negative regulator 
of CXCR4 degradation. STAM-1 differs from the other STAM isoform, STAM-2, with 
respect to the fact that they traffic different receptors, with STAM-1 being specific to the 
trafficking of CXCR4. 37  Moreover, it has been shown that STAM-1 interacts 
specifically with β-arrestin-1 and not β-arrestin-2, as interactions between STAM-1 and 
β-arrestin-2 were not detected in co-immunoprecipitation experiments. 37  
 STAM-1 contains a “coiled-coil” region (CC) in the middle of its amino acid 
sequence where, binding sites for β-arrestin-1 and HRS exist. 37, 53  STAM-1 contains an 
immunoreceptor tyrosine-based activation motif (ITAM) that binds JAK proteins, and an 
SH3 domain, where an AIP4 binding site and other signal transduction sites are located. 
54, 55  Finally, STAM-1 contains a VHS domain and an adjacent ubiquitin interacting 
motif (UIM) containing ubiquitin binding sites that are associated with interactions 
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between STAM-1 and regulatory molecules that are involved in the sorting of proteins 
in the MVB pathway, such as de-ubiquitinating enzymes (DUBs). 56  
 
 
Figure 5. STAM-1 Functional Domains. Schematic of domains within STAM-1 and 
their locations in its primary structure. 
 
Project Rationale and Research Objectives 
 Disruption of CXCR4 signaling in diseased cells overexpressing CXCR4 by 
administration of CXCR4 antagonists in humans causes various side effects, thus, a novel 
approach must be considered in order to improve the efficacy of such drug treatments, 
while simultaneously reducing these side-effects. A more effective way to approach this 
problem is to search for drugs that target downstream effectors in either the 
recycling/degradation pathway of CXCR4 or in migration-related signaling pathways. 
The interaction between STAM-1 and β-arrestin-1 is a good candidate for targeted 
therapy since it has been shown that disruption of this interaction causes an increase in 
CXCR4 degradation. Moreover, disruption of this interaction has also been shown to 
significantly reduce FAK autophosphorylation and prevent cell migration without 
affecting other signaling pathways such as ERK and AKT. Thus, targeting the interaction 
between STAM-1 and β-arrestin-1 is a novel approach to reducing upregulated CXCR4 
signaling in disease states, which should be pursued for its potential to prevent cancer 
metastasis and to be more selective at targeting particular CXCR4 signaling pathways, 
therefore potentially reducing side-effects. 
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With this goal in mind, the objective of this project is to develop an assay with 
which to monitor the interaction between STAM-1 and β-arrestin-1 in live tumor cells. 
This assay could then be used to perform high-throughput screening for potential 
inhibitors of this interaction. The identified inhibitors would be good candidates for use 
as novel therapeutics that target upregulated CXCR4 in diseased cells by both reducing 
cell surface expression and selectively inhibiting migration-related signaling. Such drugs 
could significantly reduce cancer metastasis by preventing CXCL12-mediated tumor cell 
migration, with fewer side effects.
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CHAPTER 2 
MATERIALS AND METHODS 
Reagents 
A list of all reagents and buffers used in this project, including all relevant 
information and how they were made, is located in Appendix A. 
DNA 
A summary of all DNA used throughout the course of these experiments, 
including all pertinent information, is listed in Table 1 below. 
Name: Vector: Received From: Reference: 
T7-STAM1-Rluc pRluc-N1(h) - Reported Here 
T7-STAM-1 pCMV10 - Malik and Marchese, 2010 
pRluc-N1(h) N/A BioSignal Packard Joly et al, 2001 
β-Arrestin1-mYFP pcDNA3.1 Addgene Violin et al, 2006 
β-Arrestin1-GFP pCMV10 Trejo Lab Lin and Trejo, 2013 
CXCR4-Rluc3 hRluc-N3 Heveker Lab Percherancier, 2005 
pEYFP-C1 N/A Clontech Bhandari, D. 2007 
pCMV10 N/A Sigma - 
pcDNA3 N/A Clontech - 
Table 1. DNA Used in Experiments. 
Construction of T7-STAM1-Rluc Fusion Protein Expression Plasmid 
 T7-STAM-1 DNA that had been constructed by a previous lab member was 
cloned into the multiple cloning site (MCS) of a BRET2TM codon humanized Rluc fusion 
protein expression vector (pRluc-N1(h); BioSignal Packard, Montreal, Quebec) such that 
the Rluc sequence would be located at the 3’ (expressed at the C-Terminal) end of the 
T7-STAM-1 sequence. 37  
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Primers. Custom primers (Forward: 5’-ATATAAGCTTAGCTATGGCTAG 
CATGACTGGTG-3’ Reverse: 5’-ATATGGGCCCTAGCAGAGCCTTCTGAGAATA 
TG-3’) were ordered from Eurofins Genomics and were received as ~500µg lyophilized 
pellets, which were resuspended in ~500µL of nano-purified water to produce 100µM 
stock solutions. From each of these, 20µL was diluted in 80µL nano-purified water to 
yield 20µM working solutions.  
PCR. PCR was performed using the Expand High Fidelity PCR System (Roche). 
Sequentially, nano-purified water, 10X Expand High Fidelity PCR buffer containing 
15mM MgCl2, each 20µM primer, 100ng/µL T7-STAM-1 DNA, 10mM dNTP solution, 
and Taq polymerase were added to a PCR tube in the volumes listed in Table 2. The 
reaction was then run in a GeneAmp® PCR system thermocycler (Model 9700; Applied 
Biosystems) under the conditions shown in Table 3. 
Reagent Volume 
H2O 28µL 
PCR Buffer 5µL 
S1-Luc-HindIII-F 2µL 
S1-Luc-ApaI-R 2µL 
T7-STAM-1 DNA 10µL 
dNTP 2µL 
Taq Polymerase 1µL 
Total: 50µL 
Table 2. PCR Reagents and Volumes. 
Phase Temperature Time 
Denaturing 94˚C 1min 
Annealing 50˚C 1min 
Extension 72˚C 2min 
# Cycles 30 
Holding 4˚C - 
Table 3. PCR Reaction Conditions. 
  
21 
Gel Verification and Extraction. The PCR product was visualized by adding 
15µL 6X loading dye (Qiagen) and 5µL of 10mg/mL ethidium bromide to 50µL of PCR 
product sample and subjecting it to electrophoresis on a 1% agarose gel (1g agarose in 
100mL 1X TAE buffer) at 130V for 1 hour with a 10 Kb ladder (Promega). The gel was 
then viewed under UV light using a Fisher Scientific UV light box (Figure 7, Chapter 3). 
The band resulting at approximately 1.6 Kb was cut from the gel and purified using a 
Qiagen QIAquick Gel Extraction kit, according to the manufacturer’s protocol. The 
concentration of this product was determined using a Nanodrop 8000 spectrophotometer 
apparatus (Thermo Scientific).  
Restriction Enzyme Digestion. The PCR product (Insert) and pRluc-N1 (Vector) 
were separately combined in Eppendorf tubes with 10µg/µL ApaI restriction enzyme 
(Promega), 10x Promega Buffer A, 10mg/mL BSA, and nano-purified water in volumes 
corresponding to those listed in Table 4 and incubated at 37˚C for 1 hour. 
Reagent Vector Insert 
H2O 18.5 µL 13.5 µL 
Buffer A 5 µL 5 µL 
BSA 0.5 µL 0.5 µL 
ApaI 1 µL 1 µL 
DNA 25 µL 30 µL 
Total Volume = 50 µL 50 µL 
Table 4. ApaI Digest Reagents and Volumes. Volumes shown for separate digest 
reactions of the pRluc-N1 vector and the PCR product insert. 
 
The products of the ApaI digestion were purified using a Qiagen PCR purification 
kit according to the manufacturer’s protocol, and the concentrations were measured using 
a Nanodrop 8000 spectrophotometer (Thermo Scientific). Purified DNA from each 
digestion was then combined in separate Eppendorf tubes with 10µg/µL HindIII 
restriction enzyme (Promega), 10x Promega Buffer E, 10µg/µL BSA, and nano-purified 
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water in volumes corresponding to those listed in Table 5 and incubated at 37˚C for 1 
hour.  
Reagent Volumes for Both Digestions 
H2O 0.7 µL 
Buffer E 3 µL 
BSA 0.3 µL 
HindIII 1 µL 
DNA 25 µL 
Total Volume = 30 µL 
Table 5. HindIII Digest Reagents and Volumes. Volumes shown for both digest 
reactions run separately with each product from ApaI digestion. 
 
Ligation. The products of the HindIII digestion were purified using the same 
Qiagen PCR Purification kit mentioned previously, and their concentrations were 
determined using a Nanodrop 8000 spectrophotometer (Thermo Scientific). The purified 
DNA was then combined separately at a 1:1 and 1:3 ratio of vector to insert. Ligation of 
the insert into the vector was carried out by addition of nano-purified water, 10X T4 
ligation buffer (Promega), and T4 DNA ligase (Promega) in volumes corresponding to 
those listed in Table 6, and incubated at 4˚C overnight. 
Reagent 1:1 1:3 
H2O 3 µL 1 µL 
Insert DNA 7 µL 12 µL 
Vector DNA 7 µL 4 µL 
Ligation Buffer 2 µL 2 µL 
Ligase 1 µL 1 µL 
Total Volume = 20 µL 20 µL 
Table 6. Ligation Reaction Reagents and Volumes. 
Transformation of Bacteria. 50µL of competent DH5α-F’ E. coli cells (in 
100mM CaCl2 and 15% glycerol) were inoculated separately with 3µL of each ligation 
product. The samples were incubated for 30 minutes on ice, heat shocked in a 42˚C water 
bath for 2 minutes, and cooled on ice for a further 2 minutes. 600µL of LB broth was 
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added to each sample, which were then incubated at 37˚C for 30 minutes. The 
transformed cells were then centrifuged at 3000 rpm for 3 minutes and the resulting 
supernatant was carefully aspirated such that approximately 100µL remained, and the 
solution was mixed to dissolve the pellet. The samples were then seeded onto LB agar 
plates containing 25mg/mL kanamycin (Appendix A), two for each insert to vector ratio 
that were divided into 100µL and 50µL volumes. The plates were incubated for 
approximately 18 hours at 37˚C. 10 colonies were randomly selected from the plates and 
individually inoculated into 5mL of LB broth containing 10µL of 25mg/mL kanamycin 
(Sigma) and incubated overnight in a 37˚C orbital shaker. The following day, DNA was 
purified from each sample using a Promega PureYield Plasmid miniprep kit. 
Screening for Inserts. Purified plasmids were digested with ApaI and HindIII 
(combined with the reagents listed in Table 7) according to the protocol described for the 
previous digestion reaction. 
Reagent Volume 
H2O 6.8 µL 
Digestion Buffer 2 µL 
BSA 0.2 µL 
E. Coli Culture 10 µL 
ApaI 0.5 µL 
HindIII 0.5 µL 
Total = 20 µL 
Table 7. T7-STAM1-Rluc Diagnostic Restriction Digest Reagents and Volumes. 
Each sample was then purified using a Promega PureYield Plasmid miniprep kit 
and subjected to electrophoresis on a 1% agarose gel and viewed under UV light using a 
Fisher Scientific UV light box to determine if any of the transformations were successful. 
The sample corresponding to lane 2 (Figure 8, Chapter 3) was selected and the bacterial 
culture that it was grown in was inoculated into 250mL of LB broth in order to prepare a 
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working solution of DNA, according to the large scale DNA extraction protocol 
described below. 
DNA Sequencing. The remaining purified DNA (~20µL) was sent to be 
sequenced by ACGT company (Wheeling, IL). The results of the sequencing analysis 
confirmed that the identity of the cloning product was the desired T7-STAM1-Rluc, as 
represented in the nucleotide and amino acid sequence and plasmid map displayed in 
Figures 9 and 10 (Chapter 3). 
Large Scale DNA Extraction 
All large scale working DNA solutions used in these experiments were prepared 
using the following protocol. DH5α-F’ E. coli cells are transformed with the desired 
DNA by pipetting 100µL of the competent cells into an Eppendorf tube and adding 1µL 
of the DNA to be prepared. The cells are incubated on ice for 30 minutes and then heat 
shocked in a 42˚C water bath for 2 minutes. The cells are then placed back on ice and 
incubated for 2-10 minutes. 600µL of LB broth is then added and the tubes are incubated 
at 37˚C for at least 20, but never longer than 60, minutes. 50µL of the cells are then 
seeded on an LB agar plate containing 25µg/µL kanamycin or 50µg/µL ampicillin, 
corresponding to the resistance gene contained in the plasmid of interest. Plates are then 
placed upside down in a Precision incubator and incubated at 37˚C overnight. 
The following day, an isolated colony is selected from the plate using an 
inoculating loop and inoculated in 5mL of LB broth containing 25µg/µL kanamycin or 
50µg/µL ampicillin in a 15mL round-bottomed Falcon tube and placed into an orbital 
shaker for 7 hours at 250 rpm and 37˚C. The bacterial suspension is then used to 
inoculate 250mL of LB broth in a 1L flask containing 100mg/mL antibiotic, which is 
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placed into an orbital shaker at 250 rpm and 37˚C for approximately 18 hours. The 
DNA of interest is then isolated from the bacterial cells using a Qiagen HiSpeed Plasmid 
Maxi kit according to the manufacturer’s instructions. 
Cell Lines Used 
 HeLa human cervical cancer cell lines (obtained from American Type Culture 
Collection; Manassas, VA; Cat: CCL-2; Lot: 63226283) were maintained in Dulbecco’s 
Modified Eagle Medium – High Glucose (DMEM; Sigma-Aldrich, St Louis, MO; Cat: 
D5796) containing L glucose, L-glutamine, and sodium bicarbonate, supplemented with 
10% fetal bovine serum (FBS; Sigma-Aldrich; Cat: F0926; Batch: 16A164) in a 
humidified atmosphere at 37˚C and 5% CO2. 
Transfection of DNA 
Transfection of DNA was performed with cells that had been cultured in either 
10-cm or 6-well plates using polyethylenimine (PEI) in a biological safety cabinet to 
maintain sterility. For these experiments, cells were typically 90-100% confluent at the 
time of transfection.  
Transfections were performed by aliquoting appropriate amounts of DNA for 
each transfection condition into Eppendorf tubes, to which 500µL of Opti-MEM (Gibco, 
Grand Island, NY) is added, and the solution is incubated at room temperature for 5 
minutes. Additionally, a stock solution of PEI (Polysciences, Inc., Warrington, PA) at a 
concentration of 1mg/mL in 30% ethanol (Sigma-Aldrich) is aliquoted into Opti-MEM at 
a ratio of 20µL PEI to 500µL Opti-MEM for each transfection condition, and incubated 
at room temperature for 5 minutes. This solution is then pipetted into the DNA/Opti-
MEM solution and the mixture is incubated for 15 minutes at room temperature to allow 
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for complex formation. The solution is subsequently added drop-wise to cell cultures 
and incubated overnight at 37˚C and 5% CO2. 
Co-Immunoprecipitation 
 Co-immunoprecipitation was performed in HeLa cells transfected with 5µg of T7-
STAM1-Rluc DNA and 5µg β-arrestin1-GFP DNA grown in 10cm tissue culture plates, 
according to the protocol outlined above. After 24 or 48 hours, transfected cells were 
harvested on ice by aspirating the media, washing the cells once with cold Dulbecco’s 
Phosphate Buffered Saline (DPBS; Sigma-Aldrich) solution, and scraping the cells in 
500mL (for 10cm plates) of Co-Immunoprecipitation buffer (50mM Tris HCl (pH 7.5), 
150mM NaCl, 0.5% NP-40, and 10µg/mL each of Aprotinin, Pepstatin A, and 
Leupeptin). Cells from each transfection condition were transferred into individual 
Eppendorf tubes and placed on a rocker at 4˚C to allow the cells to solubilize. Each 
solution was sonicated at 11% for 10 seconds on ice, and cleared cell lysates were 
generated by centrifugation at 14,000 rpm and 4˚C for 30 minutes. The resulting 
supernatant was carefully transferred to a clean Eppendorf tube. The concentration of the 
cleared lysate was then determined using a PierceTM BCA Protein Assay Kit (Thermo 
Scientific, Rockford, IL) according to the manufacturer’s instructions, and read at 562nm 
on a PowerWaveX 340 (Bio-Tek Instruments, Inc., Winooski, VT). The concentrations 
were then equalized to the lowest protein concentration by addition of Co-IP buffer. An 
aliquot from each of the adjusted samples representing input was saved in a fresh 
Eppendorf tube with an equal volume of 2X sample buffer (Apendix A; 8% SDS, 10% 
Glycerol, 0.7M β-mercaptoethanol, 37.5mM Tris HCl pH 6.5, 0.003% bromophenol 
blue) and stored at -20˚C. 1µL of the IP antibody (T7 goat) was added to remaining 
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samples, which were left rocking at 4˚C overnight. The following day 10µL of a 50% 
slurry of protein-A agarose beads (Roche Diagnostics, Indianapolis, IN) equilibrated with 
Co-IP buffer, was added to each sample and rocked at 4˚C for a further 60 minutes. The 
tubes were then centrifuged for 5 seconds at 10,000 rpm, and the supernatant was 
aspirated carefully without disrupting the pelleted beads. The beads were then washed 
with 750µL of cold Co-IP buffer and re-centrifugation. This wash step was repeated 
twice more. After the final wash step, the remaining buffer was aspirated and 20µL of 2X 
sample buffer was added to the beads and the samples were boiled in a heat block for 10 
minutes at 100˚C to elute the bound proteins. 10µL of each sample, along with 10µL of 
each cleared lysate sample was carefully loaded using a microtip onto a 10% acrylamide 
SDS-PAGE gel, prepared according to the protocol described below. The samples were 
subjected to SDS-PAGE, Western blot transfer, and immunoblot analysis according to 
the protocols described below.  
Of note, initial co-immunoprecipitation results yielded a significant band present 
at the molecular weight of β-arrestin1-GFP in control conditions where β-arrestin1-GFP 
was transfected with empty T7-STAM-1 expression vector. It is not expected that β-
arrestin1-GFP could co-immunoprecipitate with a T7 antibody if T7-STAM-1 proteins 
are not present, however, it is well known that β-arrestin proteins have a propensity to 
bind non-specifically with immunoglobulin beads. 57  However, substituting the use of 
Triton-X100 detergent with a stronger Nonidet-P40 (NP40) detergent in the buffer in 
which co-immunoprecipitation was performed reduced this amount of background 
binding drastically. 
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Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
All SDS-PAGE was performed as follows. A Bio-Rad Mini-PROTEAN 3 Cell 
system was used to cast an SDS-polyacrylamide gel by combining corresponding 
volumes of the reagents listed in Table 8, in the order listed, in a 50 mL conical tube. The 
solution was then pipetted between a spacer plate and a short plate up to ½” from the top 
of the plate to prepare the 10% acrylamide “running” gel. 60µL of 2-propanol was 
pipetted on top of the mixture between the plates in order to level out the top surface of 
the resulting gel. 
Reagent Volume 
Sterile Filtered H2O 0.9mL 
0.75M Tris-HCl pH 8.8 2.5mL 
10% SDS 50µL 
30% Acrylamide/Bis-
acrylamide solution (Sigma) 1.52mL 
10% APS 30µL 
TEMED 5µL 
Table 8. 10% Acrylamide SDS-PAGE Running Gel Reagents and Volumes. 
After allowing the running gel to polymerize between the plates for 
approximately 20 minutes, the 2-propanol was rinsed off using de-ionized water. The 
reagents listed in Table 9 were then combined in corresponding volumes in a 50mL 
conical tube, in the order listed, in order to prepare the 3% acrylamide “stacking” gel. 
The combined reagents were pipetted between the plates, on top of the running gel, and 
either a 10- or 15-well comb was inserted. 
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Reagent Volume 
Sterile Filtered H2O 1.0 mL 
0.75M Tris-HCl pH 6.5 250 µL 
10% SDS 22.5 µL 
30% acrylamide 200 µL 
10% APS 25 µL 
TEMED 2.5 µL 
Table 9. 3% Acrylamide SDS-PAGE Stacking Gel Reagents and Volumes. 
After the stacking gel had been allowed to polymerize (approximately 20 
minutes), the combs were gently removed from between the plates and the plates are 
placed into a Mini-PROTEAN 3 Electrophoresis Module Assembly (Bio-Rad). The 
electrode assembly is then placed into a mini-tank with enough 1X SDS running buffer 
(Appendix A) to cover the top of the short plate. The samples to be run are then carefully 
loaded using a microtip into the wells created by the comb in the stacking gel. After the 
samples are loaded the mini-tank is filled completely with 1X SDS running buffer and the 
lid is placed on top of the assembly connecting the red and black leads to corresponding 
ends of the electrode assembly. The electrical leads are plugged into a Thermo Scientific 
EC105 electrophoresis power supply and the apparatus is run at approximately 157 volts 
for 1 hour. 
Western Blot Transfer 
Protein samples resolved by SDS-PAGE were transferred by Western blot onto 
0.45µm nitrocellulose membranes (GE Healthcare). This was done by, first, removing the 
gel from between the two plates that have been removed from the Electrophoresis 
Module assembly, and equilibrating it with 1X transfer buffer (Appendix A). Secondly, 
the gel is then assembled into a “sandwich” with the nitrocellulose membrane in a Mini-
Trans-Blot® Electrophoretic Transfer Cell apparatus (Bio-Rad) according to the 
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manufacturer’s instructions. This assembly is then connected to the electrophoresis 
power supply and run at approximately 100V for 1 hour in 1X transfer buffer. 
Immunoblot Analysis 
Nitrocellulose membranes containing the transferred proteins were removed from 
the transfer apparatus and blocked in a 5% non-fat milk solution in Tris-buffered saline 
(20mM Tris-HCl pH 7.5, 150mM NaCl) containing 0.05% TWEEN-20 (TBST) for 30 
minutes at room temperature while rocking in order to prevent antibodies from binding to 
proteins non-specifically in the membrane. Subsequently the membranes were probed for 
the presence of certain proteins by incubation in solutions of 5% non-fat milk in TBST 
with a specific antibody overnight. The following day the membranes were washed three 
times for 5 minutes with TBST. After washing, the membranes were incubated in a 
solution of 5% non-fat milk in TBST containing horseradish peroxidase (HRP)-
conjugated secondary antibody for 30 minutes at room temperature while rocking. 
Following incubation, the membrane was washed with TBST, once for 5 minutes and 
four times for 10 minutes. 
Proteins were visualized by incubating the membrane in enhanced 
chemiluminescence (ECL) reagent (DURA extended duration substrate, Thermo 
Scientific) and placing it into a Bio-Rad Chemi-DocTM Touch Imaging System. This 
machine was used to take various images of the membrane using the chemiluminescence 
application at various exposure times. 
Antibodies Used 
 All antibodies used in the experiments throughout this project are listed in Table 
10 including all pertinent information. 
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Name Type Vendor Cat. # 
Anti-T7 Goat polyclonal Abcam ab9138 
Anti-GFP Mouse monoclonal Proteintech 66002-1-lg 
Anti-STAM-1 Rabbit polyclonal Proteintech 12434-1-AP 
Table 10. Antibodies Used in this Project. Includes animal each was obtained from, as 
well as the vendor from whom it was purchased, and corresponding catalogue number. 
 
BRET 
In general, all BRET experiments were performed according to the following 
protocol, unless otherwise stated. To begin, cells in 10cm plates were transfected with 
fusion protein DNA, according to the DNA transfection protocol described above. 
Plating of Transfected Cells in 96-Well Plates. The following day, cells were 
washed with 10mL of DPBS (Sigma-Aldrich) and detached using 2mL of 0.05% trypsin-
EDTA (1X; Gibco) for 5 minutes at 37˚C, 5% CO2. 4mL of DMEM supplemented with 
10% FBS was then added to each dish, the cells were fully resuspended, and each 
solution was transferred into separate 15mL Falcon tubes for each transfection condition. 
20µL of each solution was then transferred into separate Eppendorf tubes and the number 
of cells in each sample was counted using a BioRad TC10 Automated Cell Counter. The 
remaining cell suspensions were centrifuged at 1000xg for 2.5 minutes to pellet the cells 
and the supernatant is removed by aspiration. The number of cells counted in each 
Eppendorf tube was then used to calculate the amount of DMEM (supplemented with 
10% FBS) needed to achieve a concentration of 300,000cells/0.2mL. The calculated 
volume was then added, the cells were resuspended by vortexing, and 200µL of cells is 
pipetted in triplicate (twice if doing ligand/vehicle stimulation) to wells of a white, clear 
bottomed, tissue culture-treated 96-well plate. The plate was then left in a 37˚C, 5% CO2 
incubator overnight. 
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BRET Measurement. The following day the media was carefully aspirated, 
and the cell were washed with 200µL of DPBS containing 0.1% D-glucose twice. 90µL 
of DPBS containing 0.1% D-glucose was then carefully added to each well, and if the 
cells were to be stimulated with ligand, 90µL 100nM CXCL12 (Protein Foundry, 
Milwaukee, WI), or a 100nM BSA (Roche) in DPBS containing 0.1% D-glucose vehicle 
solution, were each added to half of the wells corresponding to each transfection 
condition. The cells were then incubated for 15 minutes at 37˚C and 5%CO2. A 
FlexStation® 3 Multi-Detection Reader with Integrated Fluid Transfer (Molecular 
Devices, Sunnyvale, CA) was then used to measure the total fluorescence emission at 
530nm in each well following machine excitation at 470nm. White tape was then placed 
over the clear bottoms of the wells prior to automated addition of 10µL of 50µM 
coelenterazine(h) (Nanolight, Pinetop, AZ) into each well using the FlexStation3 fluidics 
module. Luminescence emission at 470nm and 530nm was then measured in each well 
for a period of 5 minutes, during which initial luminescence emission magnitudes reach a 
peak value. A single “total luminescence” reading was subsequently taken in each well 
by selecting “All” wavelengths to be measured in the SoftMax Pro software. A “kinetic” 
read of the luminescence emission at 470nm and 530nm was then resumed, and 
measurements were taken over an additional 30 to 50 minute period.  
BRET Data Analysis. The raw luminescence emission values for each well 
obtained from the BRET measurements were exported into an Excel file, and an average 
among the three wells for each transfection condition was taken separately for 470nm and 
530nm values at each time point. A BRET ratio was then calculated for each transfection 
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condition at each time point by dividing the luminescence emission at 530nm by the 
luminescence emission at 470nm. 
A “Net BRET” value was subsequently calculated for each time point by 
subtracting the BRET ratio calculated for the transfection condition containing only T7-
STAM1-Rluc from the BRET ratio calculated for each transfection condition. In some 
cases, the net BRET values from all time points in each transfection condition were 
averaged, and these values were further averaged among separate experiments. The 
resulting values were then graphed in order to view the corresponding changes in net 
BRET seen between the different transfection conditions of the fusion proteins being 
studied. Occasionally, only net BRET values obtained from time points where it was 
believed that a “relevant” BRET reaction was still occurring were used to calculate the 
average net BRET value. A “relevant” BRET reaction was defined as the time points at 
which signals that appear to be significantly above baseline readings are being measured. 
All graphs presented in this project were generated using GraphPad Prism 6.0 
software. The same software was used to perform linear and non-linear regression 
analysis of the net BRET values. The “Hyperbola” equation was used as part of the non-
linear regression analysis, which generated a curve fit between data points on net BRET 
graphs. 
With respect to fluorescence and “total luminescence”, the measured values for 
each transfection condition were averaged among experiments. These values were then 
standardized by dividing the value from each transfection condition by the value for cells 
expressing only the Rluc fusion protein in each experiment. These values from each 
transfection condition were then averaged among experiments, and used to graph the 
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corresponding fluorescence or “total luminescence” value. Error bars representing the 
standard deviation were calculated from the averages among experiments. The error for 
the transfection condition in which only Rluc was expressed was calculated by taking the 
average of the values among experiments and dividing the value from each experiment 
individually by the average. The standard deviation between values was used to generate 
the error bars for this particular transfection condition.  
These standardized values were also used to calculate [YFP]/[Rluc] values, which 
were used as x values in net BRET graphs from BRET experiments between T7-STAM1-
Rluc and β-arrestin1-YFP. 
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CHAPTER 3 
RESULTS 
T7-STAM1-Rluc Expression Plasmid 
In order to detect the interaction between β-arrestin-1 and STAM-1 using BRET, 
DNA expression plasmids were needed that would express each protein fused to either 
GFP/YFP or Rluc. A β-arrestin-1-GFP expression vector was on hand that had been 
generously provided by Dr. JoAnn Trejo (UCSD, CA). 58  Therefore, a DNA expression 
vector of STAM-1 fused with Rluc needed to be constructed. 
A BRET2TM codon humanized Rluc expression plasmid (pRluc-N1(h); BioSignal 
Packard, Montreal, Quebec) was used as the cloning vector, which contains a multiple 
cloning site (MCS) located at the 5’ end of the Rluc sequence. A mammalian expression 
vector of STAM-1 tagged to T7, previously described, was subcloned into the MCS of 
pRluc-N1(h) to create a T7-STAM1-Rluc expression vector for T7-STAM-1 with Rluc 
fused to its’ C-terminus. 37  
Primer Design and PCR. A DNA fragment encoding T7-STAM-1 was amplified 
using T7-STAM-1/pcDNA3 as a template by polymerase chain reaction (PCR). Primers 
harboring HindIII and ApaI restriction endonuclease sites were designed to facilitate 
ligation of the T7-STAM-1 fragment into pRluc-N1(h) in the same reading frame as 
Rluc, and to have the stop codon removed (Figure 6; Also included in Figure 9).
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S1-Luc-HindIII-F: 5’-ATAT AAG CTT AGCT ATG GCT AGC ATG ACT GGT G-3’ 
 Clamp     HindIII         Start 
 
S1-Luc-ApaI-R:     5’-ATAT GGG CCC TAG CAG AGC CTT CTG AGA ATA TG-3’ 
 Clamp      ApaI 
Figure 6. Forward and Reverse Primers Designed to Amplify T7-STAM-1. Primers 
harboring HindIII and ApaI restriction endonuclease cleavage sites common to MCS in 
pRluc-N1(h) designed to facilitate ligation of T7-STAM-1 in frame with Rluc, with 
“Start” codon on forward primer to facilitate transcription beginning at T7 tag, and with 
“Stop” codon removed on reverse primer to facilitate transcription of Rluc fused to 3’ end 
of STAM-1 sequence. Clamp regions inserted next to cleavage sites to facilitate 
endonuclease binding. 
 
The PCR product was visualized by 1% agarose gel electrophoresis. The presence 
of a band at approximately 1.6 Kb (Figure 7) corresponds to T7-STAM-1. 
 
 
Figure 7. PCR Amplification of DNA Encoding T7-STAM-1. PCR product was 
subject to 1% agarose gel electrophoresis. Band appearing at approximately 1.6 Kb 
corresponds to amplified fragment. Molecular weight marker (MWM) in kilobases (Kb) 
is shown. 
 
Restriction Digestion, Ligation, and Bacterial Expression. The DNA fragment 
was excised from the gel, purified, and subjected to two sequential digestion reactions 
with ApaI and HindIII restriction endonucleases. The pRluc-N1(h) plasmid was similarly 
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digested with ApaI and HindIII to facilitate ligation with the amplified T7-STAM-1 
fragment. The fragment and plasmid were ligated at several molar ratios and transformed 
into DH5α-F’ E. coli. Transformants were spread on agar gel plates containing 
kanamycin for selection and plated at 37˚C overnight. Colonies were selected for 
isolation of small scale plasmid DNA. An aliquot of DNA was digested with HindIII and 
ApaI restriction enzymes to determine if T7-STAM-1 had been correctly inserted to 
pRluc-N1(h). The resulting digest was visualized by 1% agarose gel electrophoresis, and 
it was determined that 3 out of the 10 colonies contained the T7-STAM1-Rluc plasmid, 
as indicated by the presence of the plasmid backbone and the 1.6 Kb insert (Figure 8). 
 
 
Figure 8. Diagnostic Restriction Digest of T7-STAM1-Rluc. Product of ligation 
reaction between T7-STAM-1 and pRluc-N1 DNA transformed into E. coli, and DNA 
purified from 10 different colonies was subjected to digestion with ApaI and HindIII 
restriction enzymes. Products were subject to 1% agarose gel electrophoresis. Bands 
appearing at approximately 5 Kb and 1.6 Kb in bacterial samples 2, 3, and 5 are 
indicative of successful ligation of T7-STAM-1 DNA into the MCS of pRluc-N1(h). 
 
Sequencing. Purified DNA from bacterial culture 2 was confirmed by sequencing 
to be T7-STAM1-Rluc (Figure 9). 
 
 
  
38         Forward Primer 
      ATATAAGCTTAGCTATGGCTAGCATGACTGGTGà 
MCS                 HindIII   Start   T7   STAM-1 
AGATCTGGAGCTCTCGAGAATTCTCACGCGTCTGCAGGATATCAAGCTTAGCTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGCGGATCCCCTCT  <100 
  I  W  S  S  R  E  F  S  R  V  C  R  I  S  S  L  A  M  A  S  M  T  G  G  Q  Q  M  G  R  G  S  P  L  
 
TTTTGCCACCAATCCCTTCGATCAGGATGTTGAGAAAGCAACCAGCGAGATGAATACTGCTGAGGACTGGGGCCTCATTTTGGATATCTGTGATAAAGTT  <200 
 F  A  T  N  P  F  D  Q  D  V  E  K  A  T  S  E  M  N  T  A  E  D  W  G  L  I  L  D  I  C  D  K  V   
 
GGTCAGTCTCGCACTGGACCTAAGGATTGTCTTCGGTCTATTATGAGAAGAGTGAACCACAAAGATCCTCACGTTGCTATGCAGGCTTTGACTCTTCTAG  <300 
G  Q  S  R  T  G  P  K  D  C  L  R  S  I  M  R  R  V  N  H  K  D  P  H  V  A  M  Q  A  L  T  L  L  G 
 
GAGCATGTGTATCAAACTGTGGCAAAATTTTTCATTTAGAAGTATGTTCAAGAGATTTTGCTAGTGAAGTAAGCAACGTATTAAATAAGGGTCATCCTAA  <400 
  A  C  V  S  N  C  G  K  I  F  H  L  E  V  C  S  R  D  F  A  S  E  V  S  N  V  L  N  K  G  H  P  K  
 
AGTATGTGAAAAATTAAAGGCTCTTATGGTTGAATGGACAGATGAATTTAAGAATGATCCACAGCTTAGTCTAATATCAGCAATGATTAAGAACCTTAAG  <500 
 V  C  E  K  L  K  A  L  M  V  E  W  T  D  E  F  K  N  D  P  Q  L  S  L  I  S  A  M  I  K  N  L  K   
 
GAACAAGGAGTTACGTTCCCAGCTATTGGCTCTCAGGCTGCAGAACAAGCAAAAGCAAGCCCAGCTCTTGTAGCCAAGGATCCTGGTACTGTGGCTAACA  <600 
E  Q  G  V  T  F  P  A  I  G  S  Q  A  A  E  Q  A  K  A  S  P  A  L  V  A  K  D  P  G  T  V  A  N  K 
 
AAAGAAGAAGAAGATTTAGCAAAAGCCATTGAGTTGTCTCTCAAGGAACAAAGGCAGCAGTCAACCACCCTTTCCACTTTGTATCCAAGCACATCCAGTC  <700 
K  E  E  E  D  L  A  K  A  I  E  L  S  L  K  E  Q  R  Q  Q  S  T  T  L  S  T  L  Y  P  S  T  S  S  L 
 
TCTTAACTAACCACCAACATGAAGGCCGAAAAGTTCGTGCTATATATGACTTTGAAGCTGCTGAAGACAATGAACTTACTTTTAAAGCTGGAGAAATTAT  <800 
  L  T  N  H  Q  H  E  G  R  K  V  R  A  I  Y  D  F  E  A  A  E  D  N  E  L  T  F  K  A  G  E  I  I 
 
TACAGTTCTTGATGACAGTGATCCTAACTGGTGGAAAGGTGAAACCCATCAAGGCATAGGGTTATTTCCTTCTAATTTTGTGACTGCAGATCTCACTGCT  <900 
 T  V  L  D  D  S  D  P  N  W  W  K  G  E  T  H  Q  G  I  G  L  F  P  S  N  F  V  T  A  D  L  T  A 
 
GAACCAGAAATGATTAAAACAGAGAAGAAGACGGTACAATTTAGTGATGATGTTCAGGTAGAGACAATAGAACCAGAGCCGGAACCAGCCTTTATTGATG  <1000 
E  P  E  M  I  K  T  E  K  K  T  V  Q  F  S  D  D  V  Q  V  E  T  I  E  P  E  P  E  P  A  F  I  D  E 
 
AAGATAAAATGGACCAGTTGCTACAGATGCTGCAAAGTACAGACCCCAGTGATGATCAGCCAGACCTACCAGAGCTGCTTCATCTTGAAGCAATGTGTCA  <1100 
  D  K  M  D  Q  L  L  Q  M  L  Q  S  T  D  P  S  D  D  Q  P  D  L  P  E  L  L  H  L  E  A  M  C  H  
 
CCAGATGGGACCTCTCATTGATGAAAAGCTGGAAGATATTGATAGAAAACATTCAGAACTCTCAGAACTTAATGTGAAAGTGATGGAGGCCCTTTCCTTA  <1200 
 Q  M  G  P  L  I  D  E  K  L  E  D  I  D  R  K  H  S  E  L  S  E  L  N  V  K  V  M  E  A  L  S  L 
 
TATACCAAGTTAATGAACGAAGATCCGATGTATTCCATGTATGCAAAGTTACAGAATCAGCCATATTATATGCAGTCATCTGGTGTTTCTGGTTCTCAGG  <1300 
Y  T  K  L  M  N  E  D  P  M  Y  S  M  Y  A  K  L  Q  N  Q  P  Y  Y  M  Q  S  S  G  V  S  G  S  Q  V 
 
TGTATGCAGGGCCTCCTCCAAGTGGTGCCTACCTGGTTGCAGGGAACGCGCAGATGAGCCACCTCCAGAGCTACAGTCTTCCCCCGGAGCAGCTGTCTTC  <1400 
  Y  A  G  P  P  P  S  G  A  Y  L  V  A  G  N  A  Q  M  S  H  L  Q  S  Y  S  L  P  P  E  Q  L  S  S   
 
TCTCAGCCAGGCAGTGGTCCCACCATCCGCAAACCCAGCCCTTCCTAGTCAGCAGACTCAGGCCGCTTACCCAAATACAATGGTCAGTTCCGTTCAAGGA  <1500 
 L  S  Q  A  V  V  P  P  S  A  N  P  A  L  P  S  Q  Q  T  Q  A  A  Y  P  N  T  M  V  S  S  V  Q  G 
 
AACACATATCCCAGCCAGGCGCCAGTATATAGTCCTCCTCCTGCCGCTACTGCTGCTGCTGCAACTGCCGATGTCACTCTGTACCAGAATGCAGGACCTA  <1600 
N  T  Y  P  S  Q  A  P  V  Y  S  P  P  P  A  A  T  A  A  A  A  T  A  D  V  T  L  Y  Q  N  A  G  P  N 
 
ATATGCCCCAGGTGCCAAACTATAACTTAACATCATCAACTCTGCCTCAGCCCGGAGGCAGCCAACAGCCACCTCAGCCACAGCAACCATATTCTCAGAA  <1700 
  M  P  Q  V  P  N  Y  N  L  T  S  S  T  L  P  Q  P  G  G  S  Q  Q  P  P  Q  P  Q  Q  P  Y  S  Q  K  
             ßGTATAAGAGTCTT 
   ApaI         hRluc           Reverse 
GGCTCTGCTAGGGCCCGGGATCCCACCGGCTAGAGCCACCATGACTTCGAAAGTTTATGATCCAGAACAAAGGAAACGGATGATAACTGGTCCGCAGTGG  <1800  
 A  L  L  G  P  G  I  P  P  A  R  A  T  M  T  S  K  V  Y  D  P  E  Q  R  K  R  M  I  T  G  P  Q  W   
CCGAGACGATCCCGGGTATA 
Primer 
TGGGCCAGATGTAAACAAATGAATGTTCTTGATTCATTTATTAATTATTATGATTCAGAAAAACATGCAGAAAATGCTGTTATTTTTTTACATGGTAACG  <1900 
W  A  R  C  K  Q  M  N  V  L  D  S  F  I  N  Y  Y  D  S  E  K  H  A  E  N  A  V  I  F  L  H  G  N  A  
 
CGGCCTCTTCTTATTTATGGCGACATGTTGTGCCACATATTGAGCCAGTAGCGCGGTGTATTATACCAGACCTTATTGGTATGGGCAAATCAGGCAAATC  <2000 
  A  S  S  Y  L  W  R  H  V  V  P  H  I  E  P  V  A  R  C  I  I  P  D  L  I  G  M  G  K  S  G  K  S  
 
TGGTAATGGTTCTTATAGGTTACTTGATCATTACAAATATCTTACTGCATGGTTTGAACTTCTTAATTTACCAAAGAAGATCATTTTTGTCGGCCATGAT  <2100 
 G  N  G  S  Y  R  L  L  D  H  Y  K  Y  L  T  A  W  F  E  L  L  N  L  P  K  K  I  I  F  V  G  H  D  
 
TGGGGTGCTTGTTTGGCATTTCATTATAGCTATGAGCATCAAGATAAGATCAAAGCAATAGTTCACGCTGAAAGTGTAGTAGATGTGATTGAATCATGGG  <2200 
W  G  A  C  L  A  F  H  Y  S  Y  E  H  Q  D  K  I  K  A  I  V  H  A  E  S  V  V  D  V  I  E  S  W  D  
 
ATGAATGGCCTGATATTGAAGAAGATATTGCGTTGATCAAATCTGAAGAAGGAGAAAAAATGGTTTTGGAGAATAACTTCTTCGTGGAAACCATGTTGCC  <2300 
  E  W  P  D  I  E  E  D  I  A  L  I  K  S  E  E  G  E  K  M  V  L  E  N  N  F  F  V  E  T  M  L  P  
                                                                                              
ATCAAAAATCATGAGAAAGTTAGAACCAGAAGAATTTGCAGCATATCTTGAACCATTCAAAGAGAAAGGTGAAGTTCGTCGTCCAACATTATCATGGCCT  <2400 
 S  K  I  M  R  K  L  E  P  E  E  F  A  A  Y  L  E  P  F  K  E  K  G  E  V  R  R  P  T  L  S  W  P  
   
CGTGAAATCCCGTTAGTAAAAGGTGGTAAACCTGACGTTGTACAAATTGTTAGGAATTATAATGCTTATCTACGTGCAAGTGATGATTTACCAAAAATGT  <2500 
R  E  I  P  L  V  K  G  G  K  P  D  V  V  Q  I  V  R  N  Y  N  A  Y  L  R  A  S  D  D  L  P  K  M  F  
                                           
TTATTGAATCGGACCCAGGATTCTTTTCCAATGCTATTGTTGAAGGTGCCAAGAAGTTTCCTAATACTGAATTTGTCAAAGTAAAAGGTCTTCATTTTTC  <2600 
  I  E  S  D  P  G  F  F  S  N  A  I  V  E  G  A  K  K  F  P  N  T  E  F  V  K  V  K  G  L  H  F  S  
                                
GCAAGAAGATGCACCTGATGAAATGGGAAAATATATCAAATCGTTCGTTGAGCGAGTTCTCAAAAATGAACAA  <2673 
 Q  E  D  A  P  D  E  M  G  K  Y  I  K  S  F  V  E  R  V  L  K  N  E  Q   
Figure 9. T7-STAM1-Rluc Sequence Map. Representative map of the nucleotide and 
amino acid sequence of T7-STAM-1, with Rluc attached at the 3’/C-terminal end, located 
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in the pRluc-N1(h) plasmid. Based on sequencing results of ligation product. Included 
are the sequences of forward and reverse primers used, located where they are expected 
to anneal during PCR. 
 
A map of the entire resulting T7-STAM1-Rluc plasmid was then created, based 
on an existing pRluc-N1(h) plasmid map, by adding the T7-STAM-1 sequence to the 
location between the HindIII and ApaI restriction sites used to ligate the sequence into 
the MCS (Figure 10). 50  
 
 
Figure 10. T7-STAM1-Rluc Plasmid Map. Plasmid map of the T7-STAM1-Rluc 
construct created based on insertion of T7-STAM-1 into the existing pRluc-N1(h) 
plasmid map between the HindIII and ApaI restriction sites. 
 
T7-STAM1-Rluc Protein Expression. Following large-scale DNA extraction, 
HeLa cells were transfected with T7-STAM1-Rluc to test for expression of the protein. 
Whole cell lysates were analyzed by 10% SDS-PAGE, and Western blot with an antibody 
against T7. The presence of a band at approximately 100 KDa (the expected molecular 
weight of T7-STAM1-Rluc) indicates successful expression of the T7-STAM1-Rluc in 
HeLa cells (Figure 11). 
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Figure 11. T7-STAM1-Rluc Protein Expression. Western blot image of whole cell 
lysates from HeLa cells transfected with T7-STAM1-Rluc DNA and empty pRluc-N1 
vector. The presence of a band just above 100 kilodalton (KDa) is indicative of 
successful expression of T7-STAM1-Rluc in HeLa cells. Loading was confirmed by 
Ponceau stain (data not shown). 
 
T7-STAM1-Rluc and β-Arrestin1-GFP Interact 
The goal of subsequent experiments was to determine whether the T7-STAM1-
Rluc protein interacts directly with the β-arrestin1-GFP protein when co-expressed in 
HeLa cells. Co-immunoprecipitation was used to detect this interaction because the 
interaction had previously been defined by this method. 
β-Arrestin1-GFP Protein Expression. First, it was necessary to examine the 
expression of β-arrestin1-GFP in HeLa cells by transfecting increasing concentrations of 
DNA and analyzing the expression by subjecting whole cell lysates to 10% SDS-PAGE 
and Western blotting with an antibody against GFP (Figure 12). It was noticed that the 
expression of this protein produces a “doublet” band, which persisted even at low 
concentrations of transfected DNA. It is hypothesized that this doublet corresponds to a 
degradation product of the protein that is being formed in the cell. 
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Figure 12. β-Arrestin1-GFP Protein Expression. Western blot image of whole cell 
lysates from HeLa cells transfected with varying concentrations of β-arrestin1-GFP. The 
Western blot was probed with an antibody against GFP and the appearance of doublet 
bands at ~75 KDa correspond to the expected molecular weight of β-arrestin1-GFP. 
Loading was confirmed by Ponceau stain (data not shown). 
 
T7-STAM1-Rluc/βArrestin1-GFP Interaction Detected by Co-
Immunoprecipitation. In order to determine whether the Rluc moiety interferes with the 
ability of the two proteins to bind, co-immunoprecipitation experiments were performed. 
T7-STAM1-Rluc and β-arrestin1-GFP were co-expressed in HeLa cells, and as a control, 
each protein was co-transfected with empty vector corresponding to the opposite protein. 
T7-STAM-1 was also co-transfected with either β-arrestin1-GFP, or empty pCMV10 
vector. Equal amounts of cleared cell lysates from the transfected cells were incubated 
with an antibody against T7 and protein A agarose. The precipitated protein was eluted 
and analyzed by Western blotting with an antibody against GFP and STAM-1. Figure 13 
shows that β-arrestin1-GFP co-purified with both T7-STAM1-Rluc and T7-STAM-1, 
suggesting that it interacts with both proteins in HeLa cells. 
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Figure 13. Co-Immunoprecipitation of β-Arrestin1-GFP with T7-STAM1-Rluc. 
Western blot image of cleared cell lysates and lysate samples subjected to co-
immunoprecipitation with an antibody against T7 from transiently transfected HeLa cells. 
Immunoprecipitation eluates and cleared cell lysates were subject to 10%SDS-PAGE and 
Western blotting with antibodies against GFP and STAM-1 to detect for β-arrestin1-GFP, 
T7-STAM1-Rluc, or T7-STAM-1. Image is representative of three independent 
experiments. 
 
Figure 13 also shows that only one band is present for β-arrestin1-GFP in the co-
immunoprecipitated samples, which corresponds to the top band seen in the “doublet” 
produced when probing for β-arrestin1-GFP in cell lysates. This supports the notion that 
a degradation product of β-arrestin1-GFP is formed but that only one form of β-arrestin1-
GFP, presumably the non-degraded form, is capable of co-immunoprecipitating with T7-
STAM1-Rluc or T7-STAM-1. 
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Bioluminescence Resonance Energy Transfer (BRET) 
The manufacturer of the plate reader used for BRET measurements in these 
experiments stated that it was not suitable for taking BRET2 readings for reasons 
unknown to them. However, they suggested that the plate reader was capable of taking 
BRET1 measurements, therefore β-arrestin1-GFP was replaced with β-arrestin1-YFP 
(yellow fluorescent protein; plasmid purchased from Addgene) in order to perform 
BRET1 experiments with T7-STAM1-Rluc instead. 
It is believed that the co-immunoprecipitation of T7-STAM1-Rluc with β-
arrestin1-GFP is sufficient evidence that the β-arrestin1-YFP protein is capable of 
interacting with T7-STAM1-Rluc in cells. This is due to the fact that structural 
differences between GFP and YFP are limited to a single Thr203àTyr mutation in the 
central region of the protein. Moreover, the YFP moiety is still bound to the C-terminus 
of β-arrestin-1. It is therefore assumed that this will likely not cause any difference in the 
binding ability of β-arrestin1-YFP to T7-STAM1-Rluc. 
CXCR4-Rluc and β-Arrestin1-YFP Interaction Measured in Cells Using 
BRET. Prior to conducting BRET experiments between T7-STAM1-Rluc and β-
arrestin1-YFP, a positive control BRET experiment was carried out between CXCR4-
Rluc and β-arrestin1-YFP, which has previously been shown to produce a measureable 
BRET signal. 51  It was important to verify that the protocol developed here was capable 
of measuring a legitimate BRET signal. 
A representation of experimental design is depicted in Figure 14(a). HeLa cells 
grown on 10cm tissue culture plates were co-transfected with 1.0µg CXCR4-Rluc and 
1.0µg β-arrestin1-YFP, or with 1.0µg CXCR4-Rluc alone. After 24 hours, cells were 
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passaged into two 96-well plates for either fluorescence or luminescence readings. A 
plate with black walls and clear-bottomed wells was used for fluorescence measurements 
because the microplate reader utilizes an excitation lamp that is located below the well. 
Another plate with white walls and opaque-bottomed wells was used for luminescence 
emission measurements, which is measured from above the well. The opaque walls 
prevent light scattering, and thus, optimize the amount of luminescence detected. 
Cells were plated in triplicate sets of two for luminescence readings, and in a 
single triplicate set for fluorescence readings. After allowing the cells to grow in the 96-
well plates for 24 hours, cells in the white plate were serum-starved by incubation in 
90µL of “BRET buffer” (PBS containing 0.1% D-glucose) for 3 hours at 37˚C. Following 
incubation, one triplicate set of cell populations from each transfection condition in the 
white plate was stimulated with 100nM CXCL12, and the other set with 100nM BSA 
vehicle solution. These cells were then further incubated for 15 minutes.  
Immediately following incubation, a multi-channel pipette was used to add 10µL 
of coelenterazine(h) (CEZ) to cells in the white plate to a final concentration of 5µM, in 
order to initiate light emission from Rluc at ~470nm, thus, initiating the BRET reaction. 
Immediately following the addition of CEZ, luminescence emission at both 470 and 530 
nm was measured in each well every 30 seconds, for approximately 30 minutes. 
Meanwhile, the media in the black plate was replaced with 100µL of “BRET 
buffer” and the level of fluorescence was measured in each well using the plate reader by 
exciting YFP at 470nm, and measuring fluorescence emission at 530nm. This 
measurement is indicative of the amount of β-arrestin1-YFP expressed. 
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At each time point measurement a “Net BRET” value was calculated. This is 
indicative of the level of interaction between the two proteins based on being close 
enough in proximity to one another so that light transfers from the Rluc moiety attached 
to CXCR4 to the YFP moiety attached to β-arrestin-1. This is calculated, firstly, as the 
“BRET Ratio” for each time point, as represented in Equation 1, by dividing the 
luminescence emission measured from the acceptor moiety (YFP) at 530nm by the 
luminescence emission measured from the donor moiety (Rluc) at 470nm. 
                   Equation 1 
This BRET ratio value alone inherently contains a certain level of “background” 
signal, which can be determined by measuring the BRET ratio from cells expressing the 
Rluc fusion protein alone, as is represented in Equation 2. 
                        Equation 2 
Finally, the net BRET value adjusted for background signal can be calculated for 
each time point, by subtracting the “Background BRET” from the “BRET Ratio” as is 
represented in Equation 3. 
    Equation 3 
The net BRET values obtained from both populations of cells expressing CXCR4-
Rluc and β-arrestin1-YFP, which were stimulated with either CXCL12 or vehicle, were 
averaged for each time point between two experiments and were graphed against time, as 
is shown in Figure 14(b). The magnitude of the net BRET obtained from the cells 
stimulated with CXCL12 was similar to what has been reported in the literature. One 
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peculiarity however, is that the net BRET obtained from the cells stimulated with 
vehicle was negative in magnitude. A negative net BRET can occur when the BRET ratio 
between the Rluc and YFP fusion proteins is lower than that of background BRET. A 
reason this may have occurred is that the conditions of this assay were not fully 
optimized and a concentration of CXCR4-Rluc that yields the lowest background BRET 
signal had not been identified. However, by calculating the area under each curve, an 
increase in the overall magnitude of net BRET was seen in the cells that were stimulated 
with CXCL12 when compared to cells stimulated with vehicle (Figure 14(c)). At the very 
least, it can be determined from these results that the protocol is likely sufficient to detect 
a viable BRET signal. 
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Figure 14. Positive Control BRET Experiment Between CXCR4-Rluc and β-
Arrestin1-YFP. (a) Representation of the sequence of steps used in positive control 
BRET experiments. (b) Net BRET values calculated at each time point and averaged 
between two independent experiments with error bars representing the standard 
deviation. (c) The area under the average net BRET curves from cells stimulated with 
CXCL12 or vehicle were calculated separately for each independent experiment and 
subsequently averaged together and graphed with error bars representing standard 
deviation. N=2. 
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BRET Protocol Modifications. Much was learned about the nuances of 
performing BRET experiments by performing the positive control experiments. This led 
to updates to the protocol that were used for all remaining BRET experiments performed 
in this project (summarized in Figure 15). No major aspects of the protocol were omitted, 
with the exception of consolidation to a single white, clear-bottomed 96-well plate, in 
which fluorescence could also be measured. Following fluorescence measurement, white 
tape was placed underneath the plate over the clear-bottomed wells in order to measure 
luminescence. In addition, a fluidics module on the plate reader was used for addition of 
CEZ to cells. It took, at most, 2.5 min for the plate reader to distribute CEZ to the cells. 
Moreover, it was discovered that a “peak luminescence” emission level is reached 
approximately 5 minutes after addition of CEZ, and thus luminescence measurements 
began being taken after this had occurred, since the BRET signal becomes more stable as 
it enters a “slow decay” phase. Finally, a “total luminescence” measurement was added to 
the protocol in order to perform measurement of the level of Rluc fusion protein 
expression in experiments. This measurement was taken immediately prior to 
luminescence measurements at 470nm and 530nm being taken, 5 minutes after addition 
of CEZ, at which peak luminescence emission was expected to occur. This measurement 
consisted of the luminescence emission magnitude across all wavelengths between 360 
and 630nm. 
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Figure 15. Modified BRET Protocol. Representation of experimental procedure used to 
perform remaining BRET experiments, which is slightly modified from that which was 
used to perform positive control experiments shown in Figure 3-9(a). 
 
T7-STAM1-Rluc DNA Concentration Optimized. After performing the 
positive control experiments, the next step was to determine whether an interaction 
between T7-STAM1-Rluc and β-arrestin1-YFP could be detected. However, before co-
transfecting both plasmids, experiments were performed to determine the lowest 
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concentration of T7-STAM1-Rluc DNA that would yield the lowest background 
BRET signal. 
In order to determine the optimal concentration, HeLa cells were transfected with 
titrated concentrations of T7-STAM1-Rluc DNA ranging from 0.05 to 0.8µg and BRET 
ratios were obtained according to the protocol outlined in Figure 14(a). The net BRET 
values obtained over the 30-minute period for each DNA concentration were then 
averaged, as shown in Figure 16. The graph indicates that a continual increase in DNA 
concentration will cause the background BRET ratio to reach a minimum of 
approximately 0.8, and that 0.6µg of T7-STAM1-Rluc DNA is the lowest concentration 
that can achieve this minimum. Therefore, it was determined that 0.6µg of T7-STAM1-
Rluc DNA would be used for transfection in all remaining experiments. 
 
 
Figure 16. Background BRET Level Optimized. Background BRET signal measured 
at increasing concentrations of T7-STAM1-Rluc DNA. Each point represents an average 
BRET Ratio obtained for each transfection condition, which were then averaged from 
three independent experiments. Error bars represent standard deviation between 
experiments. The raw luminescence values measured for each transfection condition were 
also averaged for each transfection condition, and averaged between the three 
experiments. These values are plotted against the Y-axis on the right with error bars 
representing standard deviation between experiments. 
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T7-STAM1-Rluc and β-Arrestin1-YFP Interaction Likely Measured in 
Cells Using BRET. The next experiment sought to determine whether a BRET signal can 
be detected between T7-STAM1-Rluc and β-arrestin1-YFP intracellularly. This was 
achieved by a titration of the β-arrestin1-YFP DNA concentration that was co-transfected 
with a constant concentration (0.6µg) of T7-STAM1-Rluc DNA and measuring the 
corresponding net BRET. Net BRET values for each concentration of β-arrestin1-YFP 
were then graphed, and graphs were used to determine whether a BRET interaction is 
occurring by analyzing the shape of the resulting curve.  
It is logical to assume that if the two proteins are not interacting, net BRET would 
increase with increasing DNA concentrations in a linear fashion without saturating, due 
only to the increased occurrence of random interactions. Additionally, it is logical to 
assume that if the two proteins are interacting, only a relative maximum amount of net 
BRET could be measured with increasing DNA concentration, limited by the total 
number of expressed fusion proteins in the cell. Therefore, the graph of net BRET with 
increasing concentrations of β-arrestin1-YFP should produce a hyperbolic curve that is 
saturating at higher concentrations of β-arrestin1-YFP, if the proteins are interacting, and 
a linear, non-saturating line if the two proteins are not interacting. 
Figure 17(a) shows the net BRET values obtained between T7-STAM1-Rluc and 
β-arrestin1-YFP using an x-axis commonly used in the literature to normalize net BRET 
to the relative transfection efficiency of the YFP and Rluc fusion proteins. This is 
achieved by dividing the total fluorescence by the total luminescence emission measured 
for each transfection condition, and using this ratio as the x-value. 
 
  
52 
 
Figure 17. BRET Experiment Between T7-STAM1-Rluc and β-Arrestin1-YFP.  (a) 
Average of net BRET values from at least four independent experiments for each amount 
of β-arrestin1-YFP DNA transfected. Each point is graphed against its corresponding 
ratio of YFP fluorescence to total luminescence measurements averaged among 
experiments and normalized to 0µg β-arrestin1-YFP. Error bars represent standard 
deviation. Curve fit generated using hyperbolic non-linear regression analysis in 
Prism/GraphPad 6.0 software. Goodness of fit test produced an R2 value of 0.553, 
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indicating that the graph is trending towards saturation. (b) Raw luminescence values 
measured at 470 and 530nm for each transfection condition averaged in each experiment, 
and further averaged among experiments. Values obtained from each individual 
experiment are plotted. Error bars represent standard deviation. (c) YFP fluorescence 
measurements from each transfection condition, representing the level of β-arrestin1-YFP 
expression, normalized to 0µg β-arrestin1-YFP transfection condition. Bars represent 
average among experiments with error bars representing standard deviation. (d) Raw 
YFP fluorescence measurements from each experiment for each transfection condition 
(not normalized). Error bars represent standard deviation among triplicate measurements. 
(e) “Total luminescence” measurements from each transfection condition, representing 
expression level of T7-STAM1-Rluc, normalized to 0µg β-arrestin1-YFP transfection 
condition. Bars represent average among experiments with error bars representing 
standard deviation. (f) Raw total luminescence measurements from each experiment for 
each transfection condition (not normalized). Error bars represent standard deviation 
among triplicate measurements. RLU: Relative Luminescence Units. RFU: Relative 
Fluorescence Units. 
 
Figure 17(a) shows a curve fit that is non-linear in shape and appears to be 
approaching saturation at approximately 0.04, which is likely indicative of at least a 
slight interaction being detected between T7-STAM1-Rluc and β-arrestin1-YFP. 
It is important to note that there is a large amount of variability in net BRET 
magnitude measured between experiments, as represented by the relatively large error 
bars in Figure 17(a). This can be explained by the wide distribution of average raw 
luminescence magnitudes that were measured for each transfection condition in each 
experiment (Figure 17(b)), indicating that this variability was intra-experimental. This is 
supported by the varied β-arrestin1-YFP and T7-STAM1-Rluc expression levels seen 
among corresponding experiments (Figure 17(c) and (e)). However, the expression level 
of either fusion protein in each individual experiment (Figure 17(d) and (f)) followed a 
similar trend whereby β-arrestin1-YFP expression increased in a way that correlated to 
the concentration of DNA used, and T7-STAM1-Rluc expression was relatively equal in 
all conditions corresponding to the constant concentration of DNA that was used. It was 
assumed that varying cell density and/or viability at the time of BRET measurement was 
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a large contributing factor to this intra-experimental variability, since the cells were 
subjected to multiple harsh conditions such as being out of the incubator for 20 minutes 
and undergoing multiple treatments before readings could be taken. 
As a result of this large intra-experimental variability the hyperbolic shape of the 
curve is affected, however, the resulting net BRET values obtained by averaging each 
experiment still indicate how the net BRET obtained from varying DNA concentrations 
relate to one another. It can be concluded, therefore, that it is still possible to analyze net 
BRET values for a trend that is indicative of the nature of the interaction between the two 
proteins. This trend appears to be approaching saturation, as is supported by the goodness 
of fit test R2 value of 0.55. 
Another interesting aspect of the results in Figure 17(a) is that they also indicate 
that the magnitude of the net BRET obtained is extremely small (<0.1), which is due to 
the low efficiency of energy transfer between Rluc and YFP. It is assumed that if the 
amount of light transfer from Rluc to YFP were only 50% efficient, meaning that half of 
the light emitted by Rluc was detected at 470nm and the other half was absorbed by YFP 
and emitted at 530nm, an equal amount of light would be measured at both wavelengths 
and yield a net BRET value of 1. However, it has been well documented that the energy 
transfer seen with BRET1 (using this variant of Rluc, YFP, and the substrate 
coelenterazine (h)) is very low, and despite low energy transfer efficiency, it is still 
possible to conclude that an interaction may be being measured between T7-STAM1-
Rluc and β-arrestin1-YFP in these experiments due to the fact that the net BRET curve 
appears to be approaching saturation. 
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Finally, it can be postulated from Figure 17 that if this BRET assay were to be 
used to study the effects of various factors on the interaction between these two proteins, 
4.8µg β-arrestin1-YFP DNA would be an ideal concentration with 0.6µg of T7-STAM1-
Rluc DNA to obtain the most robust BRET signal.  
Non-Specific Interaction Between T7-STAM1-Rluc and EYFP Detected by 
BRET. Negative control BRET experiments were conducted so that a graph of net BRET 
between two proteins that are not expected to interact could be obtained for comparison 
with the shape of the curve obtained from T7-STAM1-Rluc and β-arrestin1-YFP. These 
experiments were carried out by co-transfecting increasing concentrations of the empty 
YFP plasmid with a constant amount of T7-STAM1-Rluc DNA. The resulting net BRET 
values were plotted against corresponding ratios of fluorescence to total luminescence 
measured for each transfection condition, as shown in Figure 18(a). 
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Figure 18. BRET Experiment Between T7-STAM1-Rluc and pEYFP. 
(a) Average of net BRET values from three independent experiments for each 
concentration of pEYFP DNA. Each point is graphed against its corresponding ratio of 
YFP fluorescence to total luminescence measurements averaged among experiments and 
normalized to 0µg pEYFP. Error bars represent standard deviation. Curve fit generated 
using hyperbolic non-linear regression analysis in Prism/GraphPad 6.0 software. 
Goodness of fit test produced an R2 value of 0.88. (b) Raw luminescence values 
measured at 470 and 530nm for each transfection condition averaged in each experiment, 
and further averaged among experiments. Values obtained from each individual 
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experiment are plotted. Error bars represent standard deviation. (c) YFP fluorescence 
measurements from each transfection condition, representing the level of pEYFP 
expression, normalized to 0µg pEYFP transfection condition. Bars represent average 
among experiments with error bars representing standard deviation. (d) Raw YFP 
fluorescence measurements from each experiment for each transfection condition (not 
normalized). Error bars represent standard deviation among triplicate measurements. (e) 
“Total luminescence” measurements from each transfection condition, representing 
expression level of T7-STAM1-Rluc, normalized to 0µg pEYFP transfection condition. 
Bars represent average among experiments with error bars representing standard 
deviation. (f) Raw total luminescence measurements from each experiment for each 
transfection condition (not normalized). Error bars represent standard deviation among 
triplicate measurements. RLU: Relative Luminescence Units. RFU: Relative 
Fluorescence Units. 
 
Figure 18(a) shows that the net BRET graph obtained from T7-STAM1-Rluc and 
EYFP forms a very straight line that does not appear to tend towards any maximum 
value. This supports the idea that any interactions occurring between these two proteins 
are non-specific, since it is assumed that any BRET under these conditions could only 
occur as a result of random intracellular interactions allowing the Rluc moiety to come 
within viable distance of the widely distributed YFP protein for BRET to occur. 
Therefore, it is expected that these values should result in a line that increases linearly, 
with no relative maximum net BRET being achieved. 
It is interesting to note that there is less intra-experimental variation in the net 
BRET values obtained between T7-STAM1-Rluc and EYFP than those obtained between 
T7-STAM1-Rluc and β-arrestin1-YFP, as indicated by the error bars in Figure 18(a). 
This is supported by the average raw luminescence values measured from each 
experiment (Figure 18(b)), which have more narrowly distributed magnitudes. Further, it 
can be seen from Figure 18(c) and (d) that the expression of EYFP correlates well with 
the increase in pEYFP DNA concentration, which likely resulted in lower intra-
experimental variability. Interestingly, Figure 18(e) and (f) show a trend of T7-STAM1-
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Rluc expression that appears to decrease at higher DNA concentrations, although the 
T7-STAM1-Rluc expression with 0 - 3.6 µg pEYFP are relatively similar, and produce a 
linear net BRET relationship. 
It was rather surprising, however, that the magnitude of the net BRET values, and 
the slope of the line were both higher than expected. When the magnitude of the net 
BRET values in Figure 17(a) are compared with those in Figure 18(a), it can be seen that 
the magnitude of net BRET between T7-STAM1-Rluc and β-arrestin1-YFP is lower than 
those between T7-STAM1-Rluc and pEYFP. This is the opposite of what was expected, 
since it is assumed that the occurrence of random interactions between T7-STAM1-Rluc 
and pEYFP would be less frequent than the specific interactions between T7-STAM1-
Rluc and β-arrestin1-YFP. However, it is likely that T7-STAM1-Rluc is highly localized 
intracellularly, since it has been previously shown that STAM-1 forms highly organized 
puncta in cells with and without CXCL12 stimulation. 37  Therefore, because YFP is 
known to distribute widely throughout the cytosol when it is expressed, the chances that 
it will randomly encounter T7-STAM1-Rluc are inherently very high. One possible 
interpretation of these data is that the intracellular interaction between STAM-1 and β-
arrestin-1 is simply a weak one. 
Moreover, the high level of variability seen in the experiments between T7-
STAM1-Rluc and β-arrestin1-YFP makes it difficult to compare the magnitude of the net 
BRET values between the two experiments. Therefore, the most important comparison 
that should be made between the two figures is the shape of each curve. While it is likely 
that aspects of this assay could be improved in order to see a stronger signal between 
these two proteins, the data presented here still seem to show evidence of a specific 
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interaction occurring between T7-STAM1-Rluc and β-arrestin1-YFP, which is 
measurable by BRET. 
No Increase in T7-STAM1-Rluc/β-Arrestin1-YFP BRET is Observed Upon 
Stimulation with CXCL12. Finally, it has been previously shown by co-
immunoprecipitation that the level of interaction between STAM-1 and β-arrestin-1 
increases upon stimulation of cells with CXCL12, reaching a maximal interaction at 
approximately 30 minutes. 37  Therefore, it was investigated whether there was any 
increase in interaction between T7-STAM1-Rluc and β-arrestin1-YFP detected by BRET, 
in cell populations that had been stimulated with CXCL12 compared those stimulated 
with vehicle. 
 
 
Figure 19. T7-STAM1-Rluc/β-Arrestin1-YFP BRET in Cells Stimulated with 
CXCL12 vs. Vehicle. The area under the curve formed by the net BRET values from 
each time point in two BRET experiments between T7-STAM1-Rluc and β-arrestin1-
YFP for cells that were stimulated with CXCL12 or vehicle was calculated and averaged 
among experiments for the listed transfection conditions cells. Averages graphed with 
error bars representing standard deviation between experiments. AUC: Area Under the 
Curve. 
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Calculating the area under the net BRET curve from multiple transfection 
conditions between two experiments (Figure 19) revealed that there is no significant 
difference in net BRET magnitude between cells stimulated with CXCL12 and cells 
stimulated with vehicle. This is likely due to the fact that the BRET signal is already 
maximal as a result of optimization, and that in order to observe a change in net BRET, 
the levels of either protein may need to be decreased. 
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CHAPTER 4 
DISCUSSION 
Primarily, it is pertinent to state that the results presented here, in their very 
essence, are a methods-based development of a novel BRET assay attempting to detect a 
direct interaction between STAM-1 and β-arrestin-1 expressed in a mammalian cellular 
system. With the nature of these results in mind, it can be seen that this project has, at the 
very least, laid the groundwork for a detailed method with which further studies of the 
interaction between STAM-1 and β-arrestin-1, as well as the effect of various factors on 
this interaction, could likely be performed. The assay could also potentially be applied to 
kinetic studies characterizing the binding affinity of these proteins for one another, as 
well as to examine functional outcomes of other protein interactions by measuring the 
BRET signal following overexpression, or knock-down. Of particular interest, this assay 
could potentially be applied to the search for inhibitors of the STAM-1 and β-arrestin-1 
interaction. The discovery of an inhibitor would, firstly, allow for further functional cell-
signaling assays to be performed with the inhibitor to study functional outcomes on other 
signaling molecules. Secondly, an inhibitor of this interaction could be explored as a 
possible therapeutic for the prevention of cancer metastasis. 
Various caveats, however, were encountered while attempting to establish this 
assay that leave some unanswered questions regarding both the sensitivity of the assay 
and the nature of the interaction between STAM-1 and β-arrestin-1, which need to be
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considered when moving forward with additional studies. These questions will be 
addressed in the discussion of results and future directions. 
Discussion of Results 
Successful Expression of T7-STAM1-Rluc. Transfection of mammalian cells 
with the engineered T7-STAM1-Rluc construct led to the successful expression of the 
STAM-1 protein fused at its C-terminus to an Rluc moiety that is capable of taking part 
in a reaction with the coelenterazine(h), and emitting luminescence. This conclusion is 
supported by agarose gel purification, sequencing, Western blotting, and luminescence 
measurement data. This construct is not only useful in providing opportunities for further 
study of the interaction between T7-STAM1-Rluc and β-arrestin1-YFP, but also for other 
possible future BRET studies with STAM-1 and other YFP-tagged proteins. 
Interaction Between T7-STAM1-Rluc and β-Arrestin1-GFP/YFP Verified by 
Co-IP. It is clear from the results of the co-IP experiments that T7-STAM1-Rluc protein 
interacts directly with β-arrestin1-GFP protein. However, the amount of β-arrestin1-GFP 
that was pulled down with T7-STAM1-Rluc was somewhat small, which could be 
indicative of a number of different phenomena occurring within the cell. Firstly, the 
interaction between T7-STAM1-Rluc and β-arrestin1-GFP in HeLa cells could simply be 
a weak and transient interaction. Secondly, β-arrestin-1 is known to bind to many 
different receptors, and sometimes in a somewhat non-specific manner, which may be 
causing a significant portion of β-arrestin-1-GFP to be bound to proteins other than T7-
STAM1-Rluc in different cellular compartments. 59  This may result in difficulty pulling 
down a substantial amount of β-arrestin-1-GFP with T7-STAM-1-Rluc. 
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Another possibility is that degradation of β-arrestin-1-GFP is preventing a 
larger proportion from interacting with T7-STAM1-Rluc. This may be supported by data 
obtained in this project where expression of β-arrestin-1-GFP showed a “doublet” band 
that may be indicative of formation of a degradation product of β-arrestin-1-GFP. This 
was further supported by the fact that only the top band in the doublet appeared to co-IP 
with T7-STAM1-Rluc. 
The Equipment and Protocol Are Sufficient to Perform BRET Experiments. 
A FlexStation3© Multi-Detection Reader (Molecular Devices) was available to perform 
BRET experiments. This equipment contains an apparatus capable of detecting  < 2 
fg/well firefly luciferase in a 96-well plate, luminescence emission wavelengths from 250 
to 850 nm, and performing luminescence measurements at more than one wavelength in 
each well for each time point. Although this type of plate reader has not been widely used 
to perform BRET experiments, it was reasonable to suggest that, considering the listed 
specifications, it was capable.  
The protocol that was developed to perform BRET experiments in this project 
was based on several published protocols that have previously been established. 
However, it was necessary to ensure that our application of these protocols was sufficient 
to detect a genuine protein interaction by BRET. Therefore, prior to attempting BRET 
measurements between T7-STAM1-Rluc and β-arrestin1-YFP, measurements were taken 
between proteins known to interact directly. 
An interaction between CXCR4-Rluc and β-arrestin1-YFP has previously been 
shown in the literature to be measureable by BRET. 51  Thus, this experiment was used as 
a positive control in this project to determine that the equipment and the designed 
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protocol were likely capable of detecting an interaction between two proteins by 
BRET. After obtaining what appeared to be a BRET signal between these two proteins, it 
was possible to begin optimizing the experimental conditions for detection of interactions 
between T7-STAM1-Rluc and β-arrestin1-YFP. 
Determination of the Optimal Concentration of T7-STAM1-Rluc DNA for 
Transfection. To develop a BRET assay to measure the interaction between two proteins 
that have not previously been studied by BRET, it is necessary to optimize the 
concentration of DNA for transfection of each fusion protein in order to achieve the 
optimal amount of signal. This requires separate titrations of each protein, and it is best to 
begin with the Rluc fusion protein. This is because the expression of this protein alone 
defines the background BRET for each experiment and it is ideal to work with the 
smallest concentration of DNA that yields the lowest amount of background signal. 
Following titration of T7-STAM1-Rluc DNA, it was determined that there was a 
relative minimum background BRET signal obtained with increasing DNA concentration. 
This can be seen from the sigmoidal relationship that exists between each point on the 
graph of net BRET obtained for increasing concentration of DNA, and this is supported 
by a very small error that was achieved across experiments. From analysis of this net 
BRET curve, it can be said with relatively high certainty that the lowest concentration of 
DNA that produced the relative minimum background BRET signal was 0.6 µg. 
Potential Measurement of T7-STAM1-Rluc and β-Arrestin1-YFP Interaction 
by BRET. The nature of the curve resulting from graphing an average value of the total 
fluorescence intensity for each concentration of β-arrestin1-YFP from each experiment 
divided by the average value of the total luminescence intensity for each transfection 
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amount of β-arrestin1-YFP from each experiment was not of a perfect hyperbolic 
shape as would be expected from experiments between two proteins that are directly 
interacting. However, the nonlinear regression fit of these points does not appear to 
produce a straight line, and appears as though it may be tending toward a maximal net 
BRET value in the samples with β-arrestin1-YFP. This especially seems to be supported 
by comparison to the net BRET graph of T7-STAM1-Rluc with EYFP, which produces a 
very straight line, with no trend toward a maximal signal. In addition, the trend line for 
experiments with EYFP was performed separately using a linear and a non-linear 
regression curve fit, both of which produced almost identical lines. 
The fact that the curve was not of a more obvious hyperbolic shape is likely due 
to intra-experimental error, although it may also speak to the possibility that the 
interaction between the proteins in the cell is small, which would agree with results 
obtained from co-immunoprecipitation experiments suggesting the same conclusion. It 
would be very interesting to find an inhibitor of the interaction between these proteins to 
see if, despite the fact that the amount of interaction in the cell may be small, the 
functional outcome is still large, based on previous results suggesting that the disruption 
of the interaction dramatically increases the amount of CXCR4 degradation in the cell. 
This could even be potentially advantageous as it might contribute to small effective 
doses needed to inhibit the interaction. 
It was unexpected that the net BRET values obtained between STAM1-Rluc and 
EYFP would reach such high magnitudes at higher concentrations of DNA when 
compared to net BRET values obtained between STAM1-Rluc and β-arrestin1-YFP. It 
can be postulated that when YFP is presented as a moiety attached to β-arrestin-1, it may 
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spatially localize with cellular β-arrestin proteins at the plasma membrane, and 
therefore, in a certain number of circumstances, be localized too far from STAM1-Rluc 
proteins, localized on endosomes, to yield “bystander BRET.” However, when the EYFP 
moiety is expressed alone in the cell, it would likely distribute diffusely throughout the 
cytosol, providing more opportunity for “bystander BRET” to occur. Nevertheless, it 
appears unlikely that there would be enough “bystander BRET” from random interactions 
in the cell to cause higher levels of BRET than from the two proteins directly interacting, 
since the distance between the Rluc and YFP moieties needs to be so close (10-100Å) for 
BRET to occur. If the β-arrestin-1/STAM-1 interactions in the cell are weak, transient, or 
at a low level, as suggested by other results in this project, this could possibly account for 
the ability of random interactions between ubiquitously-expressed YFP moieties and 
STAM1-Rluc moieties to exceed BRET levels at higher concentrations of DNA.  
There were no significant changes in the amount of BRET measured between 
cells that had been stimulated with CXCL12 15 minutes prior to BRET measurements 
and those that were stimulated with vehicle. The reason for this can only be suggested, 
however it seems reasonable to assume that the BRET signal in this system is already 
saturated as a result of using optimal concentrations of T7-STAM1-Rluc and β-arrestin1-
YFP DNA.  
Future Directions 
There are a few additional assay optimization steps that could be attempted in 
order to yield a BRET signal with a larger dynamic range and less error. The most 
pertinent would be to create stable cell lines expressing the two fusion proteins, which 
would ensure the ubiquitous expression of an equal amount of each fusion protein 
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throughout cell populations, and eliminate the need for transfection. This would 
improve intra-experiment variability since the magnitude of the total fluorescence, total 
luminescence, and BRET signal would not be affected by transfection efficiency, and the 
health and homeostasis of the cells would remain intact. A more obvious curved 
relationship between BRET measurements would likely be created, whose interruption by 
inhibitors would likely be more easily distinguished. 
Performing BRET experiments to look for disruption of the interaction between 
STAM-1 and β-arrestin-1 using a truncated β-arrestin-1 minigene (“25-161”) would be of 
interest, since it has been previously shown by co-immunoprecipitation to disrupt this 
interaction. 37  This could help to establish “25-161” as a viable inhibitor of this 
interaction for future experiments, and could also serve as a valid positive control for 
screening small molecule libraries for inhibitors. However, such experiments would 
require optimization of the DNA concentration for co-transfection. Transfection with the 
optimal concentrations of T7-STAM1-Rluc and β-arrestin1-YFP DNA (0.6 µg and 4.8µg, 
respectively) would leave the highest concentration of “25-161” DNA as 4.6 µg without 
exceeding the recommended 10 µg DNA per 10cm dish. The expression of this 
concentration is lower than the β-arrestin1-YFP DNA to bind to STAM-1, the expression 
of which are competing in the cell. This may mean that greater amounts of “25-161” 
DNA would need to be used. In addition, when performing titration experiments of “25-
161” DNA concentration co-transfected with T7-STAM1-Rluc and β-arrestin1-YFP 
DNA, the total DNA concentrations per plate need to be equalized with empty vector 
DNA. If the samples of prepared DNA are not at a high enough concentration, there is a 
risk that the volume of combined DNA will exceed 20 µL for each transfection condition. 
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This is another issue that could be minimized by the use of stable cell lines expressing 
the fusion proteins, since it would eliminate the need for co-transfection of T7-STAM1-
Rluc and β-arrestin1-YFP DNA with “25-161” DNA. 
It may also be possible to improve the magnitude of the BRET signal between the 
two fusion proteins, although this is not guaranteed. One way to attempt this would be to 
change the position of the Rluc and YFP moieties on the STAM-1 and β-arrestin-1 
proteins, for instance, swapping the moieties between proteins. It is possible that the 
folding of either protein may be affected by the current attached moiety and that more 
efficient folding, interaction between the two proteins, or distance between the moieties 
could be achieved. Changing the location of the YFP moiety from the C-terminus to the 
N-terminus of β-arrestin-1 is not plausible since it is known that the interaction between 
β-arrestin-1 and CXCR4 occurs through the positively charged region at the N-terminal 
end, and the YFP would likely interfere with the normal functioning of β-arrestin-1. 
Moreover, moving the Rluc moiety from the C-terminal to the N-terminal end of STAM-
1 may not be a good choice since a VHS region is located here, which is known to 
interact with regulatory molecules involved in protein sorting to the MVB pathway. Thus, 
it is possible that this may stop STAM-1 from functioning correctly. Further, either 
moiety could be moved to locations within the middle of the amino acid sequence of 
either protein. In order to do this, however, special attention needs to be paid to important 
regions involved in the correct folding or functioning of either protein.  
Unfortunately, a Z-score could not be calculated for this assay in order to speak to 
the fitness of the assay for application to HTS. This was due to the fact that DNA 
expressing proteins to produce a maximal net BRET signal was not on hand to perform 
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positive control experiments that would be needed to calculate a Z-score. However, it 
was still concluded that the dynamic range of the interaction seen here is likely not large 
enough for this assay to be used as a HTS for small-molecule inhibitors. One reason for 
assuming this was discussed previously regarding the fact that the efficiency of energy 
transfer between Rluc and YFP is low, and is likely the largest contributing factor to the 
low BRET signal intensity measured in these experiments. A solution to this problem, 
which should be considered above all other optimization strategies if BRET is to be used, 
is to consider using newer BRET technologies that have been developed in recent years 
to improve the energy transfer efficiency. Examples of these newer technologies that 
show promise for improved dynamic range include the use of Renilla GFP, nanoBRET, 
and different coelenterazine derivatives. The same principles outlined in this project 
could be used to establish a BRET signal between STAM-1 and β-arrestin-1 with a larger 
dynamic range using any of these newer technologies. 
Conclusion 
Taking into account all of these data, it can be said that a possibly weak and/or 
transient interaction occurs between T7-STAM1-Rluc and β-arrestin1-YFP 
intracellularly, which is likely being detected by the BRET method outlined here. There 
is some question as to whether the assay is sufficiently optimized for application to 
different interaction studies, for instance, screening for small molecule inhibitors. At the 
very least, there are certain aspects of this protocol that need to be optimized further, such 
as possible assay adjustments to yield a larger dynamic range. The project serves as a 
good platform, however, to begin establishing this type of assay.  
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The data presented also contributes knowledge towards the understanding of 
the nature of the interaction between STAM-1 and β-arrestin-1, and the application of a 
version of this assay that is further optimized to study their interaction could shed 
additional light on the manner by which these proteins interact. It is important that future 
experiments be pursued due to the implications in the understanding, and potential 
therapies of certain disease states, especially cancer metastasis. 
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Name of Reagent: Source: 
6X Loading Dye Promega 
Agarose Dot Scientific, Inc. 
Ethidium Bromide Sigma 
10 Kb Ladder Invitrogen 
Bovine Serum Albumin (BSA) Roche 
Glycerol Sigma-Aldrich 
Kanamycin A Monosulfate Sigma 
Ampicillin Sigma 
LB Broth Powder Fisher 
LB BactoTM Agar Powder Becton, Dickinson and Company (BD) 
Fetal Bovine Serum (FBS) Sigma 
Polyethylenimine (PEI) Polysciences, Inc. 
Tris Base Dot Scientific, Inc. 
Nonidet P-40 (NP-40) Roche 
Aprotinin Roche 
Leupeptin Roche 
Pepstatin A Roche 
Sodium Dodecyl Sulfate (SDS) Dot Scientific, Inc. 
β-mercaptoethanol Sigma 
Bromophenol Blue Sigma 
Protein-A Agarose Roche 
Acrylamide/Bis-acrylamide, 30% solution Sigma 
2-propanol Sigma 
TEMED Bio-Rad 
Ammonium Persulfate (APS) Sigma 
TWEEN-20 Dot Scientific, Inc. 
Non-Fat Powdered Milk Roundy’s 
Horseradish Peroxidase-Conjugated (HRP) 
Antibodies 
Vector 
DURA Extended Duration Substrate Fisher 
D-Glucose Sigma 
CXCL12 Protein Foundry 
DPBS Sigma 
0.05% Trypsin-EDTA Gibco 
DMEM Sigma 
Opti-MEM Gibco 
Coelenterazine(h) Nanolight Technologies 
Glacial Acetic Acid Sigma 
EDTA Sigma 
100% Ethanol Sigma 
DMSO Sigma 
Concentrated HCl Fisher 
Glycine Dot Scientific 
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Methanol VWR 
NaCl Dot Scientific 
CaCl2 Sigma 
Ponceau-S Sigma 
Precision Plus ProteinTM All Blue Standards 
Molecular Weight Marker 
Bio-Rad 
Table 11. Reagents Used in This Project. Reagents listed with corresponding vendor 
from whom they were purchased. 
 
TAE Buffer (50X) 
2M Tris Base 
1M Glacial Acetic Acid 
0.05M EDTA, pH 8.0 
dH2O 
Appropriate amount of tris base weighed and combined with appropriate volumes of 
glacial acetic acid and EDTA in partial volume of dH2O. dH2O added to adjust solution 
to final volume. Store at room temperature. To make 1X TAE buffer 80mL of 50X TAE 
is diluted in 3.92L of dH2O. 
LB Broth 
5g LB broth powder (Lennox; Thermo-Fischer) weighed and dissolved in 250mL dH2O 
in a glass bottle or 1L flask using a stir plate. Bottle/flask autoclaved at 250˚F for 40min 
using “Liquid” setting. Stored at room temperature. 
LB Agar Plates (with antibiotic) 
40g LB BactoTM Agar (Becton, Dickinson and Company) weighed and dissolved in 1L 
ddH2O in a 2L flask using a stir plate. Flask autoclaved at 250˚F for 40 min using 
“Liquid” setting. After cooling enough to handle flask comfortably with bare hands, but 
still warm enough that coagulation has not occurred, 25mg/mL kanamycin A (Sigma) in 
ddH2O added to solution to a final concentration of 100µg/mL. Solution poured into 
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plates under a flame and allowed to cool to room temperature. Plates stored upside 
down at 4˚C for up to 3 months. 
Polyethylenimine (PEI; 1mg/mL in 30% Ethanol) Stock Solution 
10mg of PEI powder (Polysciences, Inc.) is weighed and poured into a 50mL conical 
tube. 3mL of 100% ethanol is added and tube is vortexed and warmed in a 37˚C water 
bath until powder has dissolved. Solution is diluted with 7mL of DNAase/RNAse free 
H2O to final volume so that final volume is 30% ethanol. Solution filtered through a 2µm 
syringe and distributed into 100µL aliquots and stored at -80˚C. Each aliquot is single use 
only. 
Co-Immunoprecipitation Buffer 
50mM Tris-HCl, pH 7.5 
150mM NaCl 
0.5% NP-40 
10µg/mL each: Aprotinin, Pepstatin A, Leupeptin 
dH2O to final volume 
All ingredients combined in a 50mL conical tube on ice. Solution maintained on ice 
while in use and kept at 4˚C when not using. 
Protease Inhibitor Cocktail (Aprotinin, Leupeptin and Pepstatin A) 
10mg/mL solutions of each protease inhibitor made separately. 50mg Aprotinin (Roche) 
and 50mg Leupeptin (Roche) weighed and placed into a 15mL conical tube. 5mL of 
dH2O added to tube on ice and tube vortexed to dissolve powder. 10mg of Pepstatin A 
weighed and added to a tube, to which 1mL of DMSO is added. 50µL of each solution is 
combined in a sterile 650µL Eppendorf tube and stored at -20˚C. 
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1M Tris-HCl pH7.5, 0.75M Tris-HCl pH 8.8 or 6.5 
Appropriate amount of Tris Base weighed and dissolved in a partial volume of dH2O 
using a stir plate. pH meter (GeneMate) used to adjust the pH of the solution to 7.5 by 
adding concentrated HCl drop-wise. dH2O is added to solution to final volume. Solution 
is sterile-filtered and stored at room temperature. 
10% SDS Solution 
50g SDS weighed in hood and dissolved in partial volume of dH2O using stir plate. dH2O 
added to final volume. Solution sterile-filtered and stored at room temperature. 
10% APS Solution 
1g ammonium persulfate (APS) weighed and added to a 15mL conical tube. 10mL dH2O 
added and powder dissolved by vortexing. Tube wrapped with foil and stored at 4˚C for 
up to one month. 
10X SDS Running Buffer 
0.25M Tris Base 
1.92M Glycine 
0.14M SDS 
dH2O 
Appropriate amount of tris base, glycine and SDS weighed and dissolved in partial 
volume of dH2O using a stir plate. dH2O added to adjust to final volume. Dilute 400mL 
of 10X SDS Running Buffer in 3.6L of dH2O to make 1X SDS Running Buffer. 
Transfer Buffer (10X) 
0.25M Tris Base 
1.92M Glycine 
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dH2O 
Appropriate amount of tris base and glycine weighed and dissolved in partial volume of 
dH2O using a stir plate. dH2O added to adjust to final volume. Store at room temperature. 
Transfer Buffer (1X) 
Combine 400mL 10X Transfer Buffer with 800mL methanol and 2.8L dH2O. Store at 
4˚C. 
TBS-T (20X) 
3M NaCl 
0.4M Tris Base 
1% Tween-20 
Appropriate amount of tris base and NaCl weighed and dissolved in partial volume of 
dH2O using a stir plate. pH meter (GeneMate) used to adjust the pH of the solution to 7.5 
by adding concentrated HCl drop-wise. dH2O added to adjust to final volume. To make 
1X TBST 200mL of 20X TBST is diluted in 3.8L of dH2O. 
2X Sample Buffer 
8% SDS 
10% Glycerol 
0.7M β-Mercaptoethanol 
37.5mM Tris-HCl, pH 6.5 
0.0003% Bromophenol Blue 
Appropriate amount of SDS weighed and combined with appropriate volumes of glycerol 
and Tris-HCl, pH 6.5. In a biological safety cabinet appropriate volume of β-
mercaptoethanol added. Appropriate volume of bromophenol blue added and solution is 
  
77 
mixed using a stir plate until all solids have dissolved. 5mL aliquots are made and 
stored at -20˚C. 
BRET Buffer 
Dulbecco’s Phosphate Buffered Solution (DPBS) 
0.1% D-Glucose 
Appropriate volume of D-glucose weighed and poured into DPBS bottle. Bottle is 
inverted several times to dissolve D-glucose. 
CXCL12 Stock Solution (1000X) 
10µM CXCL12 
1% BSA in DPBS Solution 
CXCL12 powder dissolved in appropriate volume of 1% BSA in DPBS solution and 
aliquoted into 650µL microcentrifuge tubes in a biological safety cabinet to maintain 
sterility. Tubes stored at -20˚C. 
1mM Coelenterazine(h) Stock Solution 
Coelenterazine(h) lyophilized powder received in vials that are stored at -80˚C for up to 
one year. Appropriate volume of 100% ethanol is added to directly to vial and vortexed to 
dissolve powder to make stock solution. Solution is stored at -20˚C for up to 1 month.
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